<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0904257217
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1998
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LIVIAL 2.5MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TIBOLONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        76.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ORGANON" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ORGANON
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ORGANON
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03CX01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Livial 2.5 mg tablet</p><p>The active substance is: tibolone.</p><p>This&nbsp;medicine is a hormone replacement therapy (HRT). It contains tibolone, a substance that has favourable effects on different tissues in the body, such as brain, vagina and bone. This medicine is used in postmenopausal women with at least 12 months (1 year) since their last natural period.</p><p>This medicine is used for:</p><p>Relief of symptoms occurring after menopause</p><p>During the menopause, the amount of the oestrogen produced by a woman&rsquo;s body drops. This can cause symptoms such as hot face, neck and chest (&quot;hot flushes&quot;). Livial alleviates these symptoms after menopause. You will only be prescribed this medicine if your symptoms seriously hinder your daily life.</p><p>Prevention of osteoporosis</p><p>After the menopause some women may develop fragile bones (osteoporosis). You should discuss all available options with your doctor.</p><p>If you are at an increased risk of fractures due to osteoporosis and other medicines are not suitable for you, you can use Livial to prevent osteoporosis after menopause.</p><p>&nbsp;</p><p>There are three different kinds of HRT:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oestrogen-only HRT</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Combined HRT</strong>, containing two kinds of female hormone, an oestrogen and a progestogen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Livial, </strong>which contains a substance called tibolone</p><p>Livial is different from other HRT. Instead of actual hormones (such as oestrogen and progestogen) it contains tibolone. Your body breaks down tibolone to make hormones. Its effects and benefits are similar to combined HRT.</p><p>&nbsp;</p><p>In section 6, &lsquo;Contents of the pack and other information&rsquo; you can find more information about Livial and what it is used for.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>For information on when you can start taking Livial, (including after a <strong>hysterectomy</strong>) see section</p><p>3.1 (overleaf).</p><p>&nbsp;</p><p>Medical History and regular check-ups</p><p><strong>&nbsp;</strong></p><p>The use of HRT or Livial carries risks that need to be considered when deciding whether to start taking it, or whether to carry on taking it. This is especially important if you are more than 60 years old.</p><p>&nbsp;</p><p>The experience in treating women with a premature menopause (due to ovarian failure or surgery) is limited. If you have a premature menopause the risks of using HRT or Livial may be different. Please talk to your doctor.</p><p>&nbsp;</p><p>Before you start taking or restart HRT or Livial</p><p>Your doctor will ask about your own and your family&rsquo;s medical history. Your doctor may decide to perform a physical examination. This may include an examination of your breasts and /or an internal examination, if necessary.</p><p>&nbsp;</p><p><strong>&rarr;Tell</strong><strong> </strong><strong>your</strong><strong> doctor </strong>if you have any medical problems or illnesses.</p><p>&nbsp;</p><p>Regular check-ups</p><p>Once you have started on Livial, you should see your doctor for <strong>regular check-ups </strong>(at least once a year). At these check-ups, discuss with your doctor the benefits and risks of continuing with Livial.</p><p>Go for regular breast screening, as recommended by your doctor. <u>Be sure to</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; go for <strong>regular breast screening </strong>and <strong>cervical smear </strong>tests</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; regularly <strong>check your breasts </strong>for any changes such as dimpling of the skin, changes in the nipple, or any lumps you can see or feel.</p><p>2.1&nbsp;&nbsp;&nbsp; Some women should not take Livial Do not take Livial</p><p>If any of the following applies to you. If you are not sure about any of the points below, <strong>talk to your doctor </strong>before taking Livial</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or have ever had <strong>breast cancer</strong>, or if you are suspected of having it</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have <strong>cancer which is sensitive to oestrogens</strong>, such as cancer of the womb lining (endometrium), or if you are suspected of having it</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any <strong>unexplained vaginal bleeding</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have <strong>excessive thickening of the womb lining </strong>(endometrial hyperplasia) that is not being treated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or have ever had a <strong>blood clot in a vein </strong>(thrombosis), such as in the legs (deep venous thrombosis) or the lungs (pulmonary embolism)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a <strong>blood clotting disorder </strong>(such as protein C, protein S, or antithrombin deficiency)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or recently have had a disease caused by blood clots in the arteries, such as a</p><p>heart attack, stroke or angina</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or have ever had a <strong>liver disease </strong>and your liver function tests have not returned to normal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a rare blood problem called &ldquo;porphyria&rdquo; which is passed down in families (inherited)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>allergic </strong>to tibolone or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>pregnant </strong>or think you might be pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>breastfeeding</strong>.</p><p>&nbsp;</p><p>If any of the above conditions appear for the first time while taking Livial, stop taking it at once and consult your doctor immediately.</p><p>&nbsp;</p><p>If you have started the menopause you should not take Livial until <strong>12 months after your last natural period. </strong>If you take it sooner than this you may have irregular bleeding.</p><p>&nbsp;</p><p>2.2&nbsp;&nbsp;&nbsp; Warning and precautions</p><p><strong>&nbsp;</strong></p><p>Talk to your doctor, pharmacist or nurse before taking Livial.</p><p>&nbsp;</p><p>If you have ever had any of the following problems, tell your doctor before you start the treatment, as these may return or become worse during treatment with Livial. If so, you should see your doctor more often for check-ups:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fibroids inside your womb</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; growth of the womb lining outside your womb (endometriosis) or a history of excessive growth of the womb lining (endometrial hyperplasia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased risk of developing blood clots (see &ldquo;Blood clots in a vein (thrombosis)&rdquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased risk of getting an oestrogen-sensitive cancer (such as having a mother, sister or grandmother who has had breast cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a liver disorder, such as a benign liver tumour</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gallstones</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; migraine or severe headaches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a disease of the immune system that affects many organs of the body (systemic lupus erythematosus, SLE)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a disease affecting the eardrum and hearing (otosclerosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a very high level of fat in your blood (triglycerides)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluid retention due to cardiac or kidney problems</p><p>&nbsp;</p><p>2.3&nbsp; Stop taking Livial and see a doctor immediately</p><p><strong>&nbsp;</strong></p><p>If you notice any of the following when taking Livial:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any of the conditions mentioned in the &quot;Do not take Livial&quot; section</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of your skin or the whites of your eyes (jaundice). These may be signs of a liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a large rise in your blood pressure (symptoms may be headache, tiredness, dizziness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; migraine-like headaches which happen for the first time</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you become pregnant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you notice signs of a blood clot, such as:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful swelling and redness of the legs</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden chest pain</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing</p><p>For more information, see &ldquo;Blood clots in a vein (thrombosis)&rdquo;.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Note: </strong>Livial is not a contraceptive. If it is less than 12 months since your last menstrual period or you are under 50 years old, you may still need to use additional contraception to prevent pregnancy. Speak to your doctor for advice.</p><p>&nbsp;</p><p>2.4&nbsp; &nbsp; HRT and Cancer</p><p><strong>&nbsp;</strong></p><p><strong>Excessive</strong><strong> </strong><strong>thickening</strong><strong> of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer)</strong></p><p><strong>&nbsp;</strong></p><p>There have been reports of an increased cell growth or cancer of the lining of the womb in women using Livial. The risk of cancer of the lining of the womb increases the longer you take the medicine.</p><p>&nbsp;</p><p>Irregular bleeding</p><p><strong>&nbsp;</strong></p><p>You may have irregular bleeding or drops of blood (spotting) during the first 3-6 months of taking Livial. But if the bleeding or spotting:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carries on for more than the first 6 months</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Starts after you have been taking Livial for more than 6 months</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carries on even after you&rsquo;ve stopped taking Livial</p><p>&nbsp;</p><p>&rarr;see your doctor as soon as possible. Breast cancer</p><p>&nbsp;</p><p>Evidence shows that taking tibolone increases the risk of breast cancer. The extra risk depends on how long you use tibolone. In studies with HRT, after stopping HRT the extra risk decreased with time, but the risk may persist for 10 years or more when women have used HRT for more than 5 years. No data for persistence of risk after stopping are available for tibolone, but a similar pattern cannot be ruled out.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_5" o:spid="_x0000_s1029"
 type="#_x0000_t202" style='width:442.8pt;height:61.8pt;visibility:visible;
 mso-wrap-style:square;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".20497mm">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-left:5.1pt;line-height:12.55pt;mso-line-height-rule:
    exactly'><b style='mso-bidi-font-weight:normal'><span style='font-family:
    "Times New Roman",serif;mso-hansi-font-family:Calibri;mso-hansi-theme-font:
    minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi;
    letter-spacing:-.05pt'>Compare</span></b><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:.45pt'><span style='font-size:12.5pt;
    font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:10.75pt;margin-bottom:
    0in;margin-left:5.1pt;margin-bottom:.0001pt;line-height:118%'><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi;letter-spacing:-.05pt'>Women</span><span style='font-family:
    "Times New Roman",serif;mso-hansi-font-family:Calibri;mso-hansi-theme-font:
    minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi'> <span
    style='letter-spacing:-.05pt'>taking</span><span style='letter-spacing:
    -.15pt'> </span><span style='letter-spacing:-.05pt'>Livial</span><span
    style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>have</span><span
    style='letter-spacing:-.1pt'> </span>a <span style='letter-spacing:-.05pt'>lower</span><span
    style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>risk</span><span
    style='letter-spacing:-.15pt'> </span>than<span style='letter-spacing:-.15pt'>
    </span><span style='letter-spacing:-.1pt'>women</span> using<span
    style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>combined</span>
    <span style='letter-spacing:-.05pt'>HRT </span>and a<span style='letter-spacing:
    -.1pt'> </span><span style='letter-spacing:-.05pt'>comparable</span><span
    style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>risk</span><span
    style='letter-spacing:3.45pt'> </span>with <span style='letter-spacing:
    -.05pt'>oestrogen-only</span><span style='letter-spacing:-.15pt'> </span><span
    style='letter-spacing:-.05pt'>HRT.</span></span><span style='font-family:
    "Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="597" height="89" alt="Text Box: Compare

Women taking Livial have a lower risk than women using combined HRT and a comparable risk with oestrogen-only HRT.
" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:442.8pt;height:61.8pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Regularly check your breasts. See your doctor if you notice any changes such as:</p><p>o&nbsp;&nbsp; dimpling or sinking of the skin</p><p>o&nbsp;&nbsp; changes in the nipple</p><p>o&nbsp;&nbsp; any lumps you can see or feel</p><p>&nbsp;</p><p>&rarr;Make an appointment to see your doctor as soon as possible Ovarian cancer</p><p>Ovarian cancer is rare &ndash; much rarer than breast cancer. The use of oestrogen-only or combined oestrogen-progestagen HRT has been associated with a slightly increased risk of ovarian cancer.</p><p>&nbsp;</p><p>The risk of ovarian cancer varies with age. For example, in women aged 50 to 54 who are not taking HRT, about 2 women in 2000 will be diagnosed with ovarian cancer over a 5-year period. For women who have been taking HRT for 5 years, there will be about 3 cases per 2000 users (i.e. about 1 extra case).</p><p>&nbsp;</p><p>With use of Livial, the increased risk of ovarian cancer is similar to other types of HRT.</p><p>2.5&nbsp; Effect of HRT on heart and circulation Blood clots in a vein (thrombosis)</p><p>The risk of <strong>blood clots in the veins </strong>is about 1.3 to 3-times higher in HRT users than in non-users, especially during the first year of taking it.</p><p>&nbsp;</p><p>Blood clots can be serious, and if one travels to the lungs, it can cause chest pain, breathlessness, fainting or even death.</p><p>&nbsp;</p><p>You are more likely to get a blood clot in your veins as you get older and if any of the following applies to you. Inform your doctor if any of these situations apply to you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are <strong>pregnant </strong>or recently had a baby</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you use <strong>oestrogens</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are <strong>unable to walk </strong>for a long time because of major surgery, injury or illness (see also section 3, If you need to have surgery)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are seriously <strong>overweight </strong>(BMI &gt;30 kg/m2)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any <strong>blood clotting problem </strong>that needs long-term treatment with a medicine used to prevent blood clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if any of your <strong>close relatives has ever had a blood clot </strong>in the leg, lung or another organ</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have <strong>systemic lupus erythematosus (SLE)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have <strong>cancer</strong>.</p><p>&nbsp;</p><p>For signs of a blood clot, see &ldquo;Stop taking Livial and see a doctor immediately&rdquo;.</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_4" o:spid="_x0000_s1028" type="#_x0000_t202" style='width:442.8pt;
 height:114.4pt;visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".20497mm">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-left:5.1pt;line-height:12.55pt;mso-line-height-rule:
    exactly'><b style='mso-bidi-font-weight:normal'><span style='font-family:
    "Times New Roman",serif;mso-hansi-font-family:Calibri;mso-hansi-theme-font:
    minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi;
    letter-spacing:-.05pt'>Compare</span></b><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:.35pt'><span style='font-size:10.5pt;
    font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:5.2pt;margin-bottom:
    0in;margin-left:5.1pt;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi;letter-spacing:-.05pt'>Looking</span><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi;letter-spacing:-.15pt'> </span><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi'>at<span style='letter-spacing:.05pt'>
    </span><span style='letter-spacing:-.1pt'>women</span> <b style='mso-bidi-font-weight:
    normal'>in<span style='letter-spacing:-.05pt'> their</span><span
    style='letter-spacing:-.1pt'> </span>50s </b><span style='letter-spacing:
    -.05pt'>who</span> <span style='letter-spacing:-.05pt'>are</span> <b
    style='mso-bidi-font-weight:normal'><span style='letter-spacing:-.1pt'>not</span><span
    style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>taking</span><span
    style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>HRT</span></b><span
    style='letter-spacing:-.1pt'>,</span> on <span style='letter-spacing:-.05pt'>average,</span>
    <span style='letter-spacing:-.05pt'>over</span><span style='letter-spacing:
    .05pt'> </span>a 5<span style='letter-spacing:-.05pt'> </span><span
    style='letter-spacing:-.1pt'>year</span><span style='letter-spacing:.05pt'>
    </span><span style='letter-spacing:-.05pt'>period,</span> <b
    style='mso-bidi-font-weight:normal'>4<span style='letter-spacing:-.15pt'> </span>to
    7<span style='letter-spacing:3.15pt'> </span>in<span style='letter-spacing:
    -.05pt'> </span>1000 </b><span style='letter-spacing:-.05pt'>would</span> <span
    style='letter-spacing:-.1pt'>be</span> <span style='letter-spacing:-.05pt'>expected</span><span
    style='letter-spacing:-.15pt'> </span>to <span style='letter-spacing:-.05pt'>get</span><span
    style='letter-spacing:.05pt'> </span>a <span style='letter-spacing:-.05pt'>blood</span><span
    style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>clot</span><span
    style='letter-spacing:-.1pt'> </span>in a <span style='letter-spacing:-.1pt'>vein.</span></span><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:19.9pt;margin-bottom:
    0in;margin-left:5.05pt;margin-bottom:.0001pt'><span style='font-family:
    "Times New Roman",serif;mso-hansi-font-family:Calibri;mso-hansi-theme-font:
    minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi;
    letter-spacing:-.05pt'>For</span><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi;letter-spacing:.05pt'> </span><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi;letter-spacing:-.1pt'>women</span><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi'> <b style='mso-bidi-font-weight:normal'>in<span
    style='letter-spacing:-.05pt'> their</span> <span style='letter-spacing:
    -.05pt'>50s</span> </b><span style='letter-spacing:-.1pt'>who</span> <span
    style='letter-spacing:-.05pt'>have</span> been<span style='letter-spacing:
    -.15pt'> </span><b style='mso-bidi-font-weight:normal'><span
    style='letter-spacing:-.05pt'>taking</span> <span style='letter-spacing:
    -.05pt'>oestrogen-progestogen</span><span style='letter-spacing:-.15pt'> </span><span
    style='letter-spacing:-.05pt'>HRT </span></b><span style='letter-spacing:
    -.05pt'>for</span><span style='letter-spacing:.05pt'> </span><span
    style='letter-spacing:-.1pt'>over</span><span style='letter-spacing:.05pt'>
    </span>5 <span style='letter-spacing:-.05pt'>years,</span><span
    style='letter-spacing:2.85pt'> </span><span style='letter-spacing:-.05pt'>there</span>
    <span style='letter-spacing:-.05pt'>will</span><span style='letter-spacing:
    .05pt'> </span><span style='letter-spacing:-.1pt'>be</span> <b
    style='mso-bidi-font-weight:normal'>9<span style='letter-spacing:-.15pt'> </span>to
    12<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:
    -.05pt'>cases</span> <span style='letter-spacing:-.05pt'>in </span>1000 </b><span
    style='letter-spacing:-.05pt'>users</span><span style='letter-spacing:-.1pt'>
    </span><span style='letter-spacing:-.05pt'>(i.e.</span> <span
    style='letter-spacing:-.05pt'>an</span> <span style='letter-spacing:-.05pt'>extra</span><span
    style='letter-spacing:-.1pt'> </span>5<span style='letter-spacing:-.15pt'> </span><span
    style='letter-spacing:-.05pt'>cases).</span></span><span style='font-family:
    "Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:.05pt'><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:26.3pt;margin-bottom:
    0in;margin-left:5.1pt;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi;letter-spacing:-.05pt'>With</span><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi'> <span style='letter-spacing:-.05pt'>use</span> of<span
    style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>Livial,</span>
    <span style='letter-spacing:-.05pt'>the</span> <span style='letter-spacing:
    -.05pt'>increased</span><span style='letter-spacing:-.15pt'> </span><span
    style='letter-spacing:-.05pt'>risk</span><span style='letter-spacing:-.15pt'>
    </span>of<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:
    -.05pt'>getting</span><span style='letter-spacing:-.15pt'> </span>a <span
    style='letter-spacing:-.05pt'>blood</span> <span style='letter-spacing:
    -.05pt'>clot</span><span style='letter-spacing:.05pt'> </span><span
    style='letter-spacing:-.05pt'>in</span> a <span style='letter-spacing:-.05pt'>vein</span><span
    style='letter-spacing:-.15pt'> </span>is<span style='letter-spacing:-.1pt'>
    </span><span style='letter-spacing:-.05pt'>lower</span><span
    style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>than</span>
    with<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:
    -.05pt'>other</span><span style='letter-spacing:3.05pt'> </span><span
    style='letter-spacing:-.05pt'>types</span> of<span style='letter-spacing:
    .05pt'> </span><span style='letter-spacing:-.1pt'>HRT.</span></span><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="597" height="158" alt="Text Box: Compare

Looking at women in their 50s who are not taking HRT, on average, over a 5 year period, 4 to 7 in 1000 would be expected to get a blood clot in a vein.
For women in their 50s who have been taking oestrogen-progestogen HRT for over 5 years, there will be 9 to 12 cases in 1000 users (i.e. an extra 5 cases).

With use of Livial, the increased risk of getting a blood clot in a vein is lower than with other types of HRT.
" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:442.8pt;height:114.4pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>Heart disease (heart attack)</p><p><strong>&nbsp;</strong></p><p>There is no evidence that HRT or Livial will prevent a heart attack.</p><p>&nbsp;</p><p>Women over the age of 60 who use oestrogen-progestogen HRT are slightly more likely to develop heart disease than those not taking any HRT. As the risk of heart disease strongly depends on age, the number of extra cases of heart disease due to use of oestrogen-progestogen HRT is very low in healthy women close to menopause, but will rise with more advanced age. There is no evidence to suggest that the risk of myocardial infarction with Livial is different to the risk of other HRT.</p><p>&nbsp;</p><p>Stroke</p><p><strong>&nbsp;</strong></p><p>Recent research suggests that HRT and Livial slightly increases the risk of having a stroke. The increased risk is seen mainly in women over 60 years old. Other things that can increase the risk of stroke include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Getting older</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Smoking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drinking too much alcohol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An irregular heartbeat</p><p>&nbsp;</p><p><strong>If</strong><strong> </strong><strong>you are worried about any of these things</strong>, talk to your doctor to see if you should take HRT</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_3" o:spid="_x0000_s1027" type="#_x0000_t202" style='width:442.8pt;
 height:101.65pt;visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAfgH38tAIAADmvAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsXX1S4zYU/78zvYPHf7UzDfkOkNnQ
gQA7naG7DOweQNhK7MG2XEkkYTud6R16gZ6lR+lJ+iQnxA67xAoxROXBEBzbeZF+fl960tN79/Ms
jpwJ5SJkycBt7jVchyYe88NkPHA/fzqvHbiOkCTxScQSOnDvqXB/Pvr+u3ekP+YkDULPAQqJ6JOB
G0iZ9ut14QU0JmKPpTSBayPGYyLhLR/XfU6mQDmO6q1Go1ePSZi4R0tSp0QS546HG5CKmHdL/SFJ
JkQAycjr58/M2xh5z6dM+snkPU+v00uuWu59mFxyJ/QHLiCXkBggcuvzC/Pb4G195VPjJYHZiMfq
fjYaOTNN5V69ahp0Jh0PTnZ7rXa3B1/gwbVm67Bx2O3OvyX4+JXPecHZmk9Cg7IvhoNcY0SqmpJM
HveutejdJ9WoEzZz2g/9VHc7cgYnoXX6eYr0Ap6HcBI2DEgypsecs2lAiS/UHRkggFz2NRqcxTcK
Retm+ivzAUlyJ5mm9xyQHrpK+ikX8j1lsaMOBi6nntTkyeRCyKxVi1s0Duw8jCL9JKLEmQ7c/fb+
YdY/FoW+uqhuE3x8M4y4MyERPDn9M++iyN8Wh5JyJwrjgXvwcBPpK1TOEl9/iyRhlB1Do6NEEQe0
oW3zo0w2fofnf3ZwdtCpdVq9s1qncXpaOz4fdmq98+Z+97R9OhyeNv9Q7Wx2+kHo+zRRTV3IabPz
SAji0ONMsJHc81hcB04MPbqQVZDUZmMpqYUuFXp+rn8e97xebIYWBujV4r/uHXRXPXjVTTm71kyo
+Mm/V2du4D8wBWfwyEAGQFnJj/Ayihg8Ei8KU9cJGP+yek7dBz2FK64zBVU1cMVvd4RT14l+SYAP
gZRcHPDFwc3igCQefHTgStfJDocS3sFn7lIejgOgnHF6wo6BSUfhnH2ytqpWR0Jey/uI6gere6Q4
Oyb8YuD2Ovv7QAreXCma+vbkOvXUgUi9SykyZmq2MjnX3LC8fkJHq3dqhaFR9JZXj0eacfIUc/fp
q/CROe4afA5NjEBgBy5Nap+vQfV/gY42G9DYG9VjB2gN3FpXN5mORiBAmeRAf4kME0fep3REPJDd
T2FMhfOBTp0rFpPEdVKSMAEXGi347TXajW6jA38tOOrA1VB6wTmJw0ipODA6XkC4oPqRawgpyREf
kii84WGB6Lkmpoh3gCS8rhBtw4lVop7IET3mIYkKJE+gnR0gtfhdTxLwBAzV05FHQxanwG9K+Wfc
rs/TxL8knFx9E2n14aeh3VbvrYF0iZnWGpk0KZyWIrUiTsCnSzl4kKe2tppViQnw32vLxbaFrlL5
+OdvFI28VtxI25QQjYK1aSqVlunvr8tIzkIsJWirlmRHbIhVsnLB2C0MnFYERhuUJ2x2hnTz1c21
VVA7ZiCvN9fb7n3BbG+beKUan0gzbDN3E9m36B0/dmTzXqch+849+ia6LiYgT1lMEzNeRj2RH+Ft
l4f12BQBLg9waMi8uzX6t8rmOTKgITfTFQW4UTWvDeQ8x/6h7igRKcsD3G2IzXwM9OOMXIyAmSkN
tH/l7R8ysI6pVzvYexT6XhOuQAZGBjacFKqUgRO2Ubiihg5bpQ4bho/1HKcRxpJg9FjNtFdv9dCz
qB7ji3ACM/Vm3jHGObNFDGZLGAy5GT248h7cv3/+5bDEEOA5F+NI2mQkTWAlGBnTn8wUBvJyeV5G
Lq7e6DHgYjMOxtlTc0fZkJNRSZRXEsQQW7R1et2pmcPWrd1TgnpCyWWlsSHk5eotXkp5yHx02x6W
1G97gbopE+NUqeFUadvQYcvnWOCqTaMIJ/JyxRbvOUuGWocYsTCJWCAzV8zMkNHWMAUZ553Mh9NT
dhf5ZkYQh9Tlh9TODUUurn4gQmcpJLpSQ0ZezDih6avQ9KG2KK8tpOGCQmTgF5gyxSjnBlHOAKb0
0KtY7LSw9bAQRupfYKGQkJzd0r0VNl6mc39jH471Bg93h1AbQyiclrtDFFLgO51mu5V5ZTCmWya5
P2wT8WZS4LfFKpVOtZwzO+ezrAB3s+Hj669wtgJc+7KErYDVgX2mVszmmsySXXGyrYB3k3xVHRt9
9UCHFfAasu56f2/b2dCF7UWsgBQyUjfSB2jG5vvtbXc3hh2ZKLGCdaeWZflaAarzeNfFcg4CKgRU
COsmKyqembY6U88O7bCRr4DObbY179OuQpaZZ9eSTWTaN75PMwx4zVQCjsnUJt1PawLDYS5GaAob
oD+N7Sgc31m2uQoq2TeuZO1bCWgHy5qvANyFLA4rsN038wqKmzbieKHMeMHUS0DefaiR8rSL8Jxs
DSzvUi4KppIINlEROHzA4UOu2NFjQa44xPhDuPdo3VnJ+DhatQqsGuqD9fqA4JKPCiuVQTk+TgxN
WTbLizNm5XwFM3BRI6zXCB0zSLMAIxQddBHc9eCajstwyUf5NCyPCCp+xIX/sL3DsiLoy9S+O+j1
DrNCR8Cwb3nh/7bXDFaaAIC17/J1cCuF2lDvv7IptYqLsfZd9Yn6huw7n3R+/TGMVYxsX1aLVfCa
8vAuTIlYBbDdUyNWQY217xwvIHxX3bdsxhqduPJj9x7WvnuJIiq2ZcXYpZQ3CZy+/poAqzA2TkBC
JVxeCZt6yDsSnLaKgbH2HVYLK/ithaxwq1jZ6ow6q5BGxVx9iBNr31G5k5Uc0YMr78Fh7buXYmKs
fYeVgBaerL0uHNa+e4mom6H7hgavvMHDHXVfYEddrH23k47xrqT2WzWUxtp3FSdBGRo7nCptGda+
azYN55lyxe9aB6++TN8qbYHMXLG2wDVDuIaluI7H3sE01r57GTfZvh1v/tc2b1fyVa0C+caunfGs
wtbUacNlLOb1R7FyY2ERB+aO3S+KplmlKiRDZVH90gqsKigq3GPEsXWDEas0BeqJ6vUEVm50t1Ry
dFnt8kgFi6FoI7zK2Qnz79Xs8p2g1+kVlN6GZ6ovXGd3CPUv8voR826pPyTJhAh9x5iTNAi9UyJJ
/v3RfwAAAP//AwBQSwMEFAAGAAgAAAAhAOFRNx/PBgAA5hsAABoAAABjbGlwYm9hcmQvdGhlbWUv
dGhlbWUxLnhtbOxZzW/cRBS/I/E/jHxvs9/NRt1U2c1uA23aKNkW9Thrz9rTjD3WzGzSvaH2iISE
KIgDlbhxQEClVuJS/ppAERSp/wJvZmyvJ+uQtI2gguaQtZ9/877fm6/LV+7FDB0QISlPel79Ys1D
JPF5QJOw590ajy6sekgqnASY8YT0vDmR3pX199+7jNd8RtMJxyIYRyQmCBglcg33vEipdG1lRfpA
xvIiT0kC36ZcxFjBqwhXAoEPQUDMVhq1WmclxjTx1oGj0oyGDP4lSmqCz8SeZkNQgmOQfnM6pT4x
2GC/rhFyLgdMoAPMeh7wDPjhmNxTHmJYKvjQ82rmz1tZv7yC17JBTJ0wtjRuZP6ycdmAYL9hZIpw
Ugitj1rdS5sFfwNgahk3HA4Hw3rBzwCw74OlVpcyz9Zotd7PeZZA9nGZ96DWrrVcfIl/c0nnbr/f
b3czXSxTA7KPrSX8aq3T2mg4eAOy+PYSvtXfGAw6Dt6ALL6zhB9d6nZaLt6AIkaT/SW0DuholHEv
IFPOtirhqwBfrWXwBQqyocguLWLKE3VSrsX4LhcjAGggw4omSM1TMsU+5OQAxxNBsRaA1wgufbEk
Xy6RtCwkfUFT1fM+THHilSAvn33/8tkTdHT/6dH9n44ePDi6/6Nl5IzawklYHvXi28/+fPQx+uPJ
Ny8eflGNl2X8rz988svPn1cDoXwW5j3/8vFvTx8//+rT3797WAHfEHhSho9pTCS6QQ7RLo/BMOMV
V3MyEa82YhxhWh6xkYQSJ1hLqeA/VJGDvjHHLIuOo0efuB68LaB9VAGvzu46Cu9FYqZoheRrUewA
tzlnfS4qvXBNyyq5eTxLwmrhYlbG7WJ8UCV7gBMnvsNZCn0zT0vH8EFEHDV3GE4UDklCFNLf+D4h
FdbdodTx6zb1BZd8qtAdivqYVrpkTCdONi0GbdEY4jKvshni7fhm+zbqc1Zl9SY5cJFQFZhVKD8m
zHHjVTxTOK5iOcYxKzv8OlZRlZJ7c+GXcUOpINIhYRwNAyJl1ZibAuwtBf0aho5VGfZtNo9dpFB0
v4rndcx5GbnJ9wcRjtMq7B5NojL2A7kPKYrRDldV8G3uVoh+hzjg5MRw36bECffp3eAWDR2VFgmi
v8yEjiW0aqcDxzT5u3bMKPRjmwPn146hAT7/+lFFZr2tjXgD5qSqStg61n5Pwh1vugMuAvr299xN
PEt2CKT58sTzruW+a7nef77lnlTPZ220i94KbVevG+yi2CyR4xNXyFPK2J6aM3JdmkWyhHkiGAFR
jzM7QVLsmNIIHrO+7uBCgc0YJLj6iKpoL8IpLLDrnmYSyox1KFHKJWzsDLmSt8bDIl3ZbWFbbxhs
P5BYbfPAkpuanO8LCjZmtgnN5jMX1NQMziqseSljCma/jrC6VurM0upGNdPqHGmFyRDDZdOAWHgT
FiAIli3g5Q7sxbVo2JhgRgLtdzv35mExUTjPEMkIBySLkbZ7OUZ1E6Q8V8xJAORORYz0Ju8Ur5Wk
dTXbN5B2liCVxbVOEJdH702ilGfwIkq6bo+VI0vKxckSdNjzuu1G20M+TnveFPa08BinEHWp13yY
hXAa5Cth0/7UYjZVvohmNzfMLYI6HFNYvy8Z7PSBVEi1iWVkU8N8ylKAJVqS1b/RBreelwE2019D
i+YqJMO/pgX40Q0tmU6Jr8rBLlG07+xr1kr5TBGxFwWHaMJmYhdD+HWqgj0BlXA0YTqCfoFzNO1t
88ltzlnRlU+vDM7SMUsjnLVbXaJ5JVu4qeNCB/NWUg9sq9TdGPfqppiSPydTymn8PzNFzydwUtAM
dAR8OJQVGOl67XlcqIhDF0oj6o8ELBxM74BsgbNY+AxJBSfI5leQA/1ra87yMGUNGz61S0MkKMxH
KhKE7EBbMtl3CrN6NndZlixjZDKqpK5MrdoTckDYWPfAjp7bPRRBqptukrUBgzuef+57VkGTUC9y
yvXm9JBi7rU18E+vfGwxg1FuHzYLmtz/hYoVs6odb4bnc2/ZEP1hscxq5VUBwkpTQTcr+9dU4RWn
WtuxlixutHPlIIrLFgOxWBClcN6D9D+Y/6jwmb1t0BPqmO9Cb0Vw0aCZQdpAVl+wCw+kG6QlTmDh
ZIk2mTQr69ps6aS9lk/W57zSLeQec7bW7CzxfkVnF4szV5xTi+fp7MzDjq8t7URXQ2SPlyiQpvlG
xgSm6tZpG6doEtZ7Htz8QKDvwRPcHXlAa2haQ9PgCS6EYLFkb3F6XvaQU+C7pRSYZk5p5phWTmnl
lHZOgcVZdl+SUzrQqfQVB1yx6R8P5bcZsILLbj/ypupcza3/BQAA//8DAFBLAwQUAAYACAAAACEA
nGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVs
c4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPsN7NN+7IzeWJMk3cc
aloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4nxpIa0cpEfUBXNoOP
VuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTLpRcWoIwGMwdKV2ed
NS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/xwQAAADIBAAALAAAA
AAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQB+Affy0AgAAOa8AAAfAAAA
AAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1sUEsBAi0AFAAGAAgA
AAAhAOFRNx/PBgAA5hsAABoAAAAAAAAAAAAAAAAALQsAAGNsaXBib2FyZC90aGVtZS90aGVtZTEu
eG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAANBIAAGNsaXBib2Fy
ZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAFAGcBAAA3EwAAAAA=
" filled="f" strokeweight=".20497mm">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-left:5.1pt;line-height:12.55pt;mso-line-height-rule:
    exactly'><b style='mso-bidi-font-weight:normal'><span style='font-family:
    "Times New Roman",serif;mso-hansi-font-family:Calibri;mso-hansi-theme-font:
    minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi;
    letter-spacing:-.05pt'>Compare</span></b><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:.35pt'><span style='font-size:10.5pt;
    font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:8.35pt;margin-bottom:
    0in;margin-left:5.1pt;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman";letter-spacing:-.05pt'>Looking</span><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
    letter-spacing:-.15pt'> </span><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'>at<span style='letter-spacing:
    .05pt'> </span><span style='letter-spacing:-.1pt'>women</span> <b>in<span
    style='letter-spacing:-.05pt'> their</span><span style='letter-spacing:
    -.1pt'> </span>50s </b><span style='letter-spacing:-.05pt'>who</span> <span
    style='letter-spacing:-.05pt'>are</span> <span style='letter-spacing:-.05pt'>not</span><span
    style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>taking</span><span
    style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>Livial</span><span
    style='letter-spacing:-.1pt'> </span>– on <span style='letter-spacing:-.05pt'>average,</span>
    <span style='letter-spacing:-.05pt'>over</span><span style='letter-spacing:
    .05pt'> </span>a <span style='letter-spacing:-.05pt'>5-year</span><span
    style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>period,</span>
    <b>3<span style='letter-spacing:-.15pt'> </span>in<span style='letter-spacing:
    2.95pt'> </span>1000 </b><span style='letter-spacing:-.05pt'>would</span>
    be <span style='letter-spacing:-.05pt'>expected</span><span
    style='letter-spacing:-.15pt'> </span>to<span style='letter-spacing:-.15pt'>
    </span><span style='letter-spacing:-.05pt'>have</span> a <span
    style='letter-spacing:-.05pt'>stroke.</span><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:34.75pt;margin-bottom:
    0in;margin-left:5.1pt;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi;letter-spacing:-.05pt'>For</span><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi;letter-spacing:.05pt'> </span><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi;letter-spacing:-.1pt'>women</span><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi'> in <span style='letter-spacing:-.05pt'>their</span><span
    style='letter-spacing:.05pt'> </span>50s<span style='letter-spacing:-.1pt'>
    </span><span style='letter-spacing:-.05pt'>who</span> are<span
    style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>taking</span><span
    style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>Livial,</span>
    <span style='letter-spacing:-.05pt'>the</span> <span style='letter-spacing:
    -.05pt'>figure</span> <span style='letter-spacing:-.05pt'>would</span> be <b
    style='mso-bidi-font-weight:normal'>7<span style='letter-spacing:-.15pt'> </span>in<span
    style='letter-spacing:-.05pt'> 1000</span> </b><span style='letter-spacing:
    -.05pt'>(i.e.</span><span style='letter-spacing:-.15pt'> </span>an <span
    style='letter-spacing:-.05pt'>extra</span><span style='letter-spacing:-.1pt'>
    </span>4<span style='letter-spacing:3.05pt'> </span><span style='letter-spacing:
    -.05pt'>cases).</span></span><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:14.7pt;margin-bottom:
    0in;margin-left:5.1pt;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman";letter-spacing:-.05pt'>Looking</span><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
    letter-spacing:-.15pt'> </span><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'>at<span style='letter-spacing:
    .05pt'> </span><span style='letter-spacing:-.1pt'>women</span> <b>in<span
    style='letter-spacing:-.05pt'> their</span><span style='letter-spacing:
    -.1pt'> </span>60s </b><span style='letter-spacing:-.05pt'>who</span> <span
    style='letter-spacing:-.05pt'>are</span> <span style='letter-spacing:-.05pt'>not</span><span
    style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>taking</span><span
    style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>Livial</span><span
    style='letter-spacing:-.1pt'> </span>– on <span style='letter-spacing:-.05pt'>average,</span>
    <span style='letter-spacing:-.05pt'>over</span><span style='letter-spacing:
    .05pt'> </span>a <span style='letter-spacing:-.05pt'>5-year</span><span
    style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>period,</span>
    <b>11<span style='letter-spacing:2.85pt'> </span>in<span style='letter-spacing:
    -.05pt'> </span>1000 </b><span style='letter-spacing:-.05pt'>would</span> <span
    style='letter-spacing:-.1pt'>be</span> <span style='letter-spacing:-.05pt'>expected</span><span
    style='letter-spacing:-.15pt'> </span>to <span style='letter-spacing:-.05pt'>have</span>
    a<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:
    -.05pt'>stroke.</span><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="597" height="142" alt="Text Box: Compare

Looking at women in their 50s who are not taking Livial – on average, over a 5-year period, 3 in 1000 would be expected to have a stroke.
For women in their 50s who are taking Livial, the figure would be 7 in 1000 (i.e. an extra 4 cases).
Looking at women in their 60s who are not taking Livial – on average, over a 5-year period, 11 in 1000 would be expected to have a stroke.
" src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:442.8pt;height:101.65pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026" type="#_x0000_t202" style='width:442.8pt;
 height:25.8pt;visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".20497mm">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:0in;margin-right:20.9pt;margin-bottom:
    0in;margin-left:5.1pt;margin-bottom:.0001pt;line-height:100%'><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi;letter-spacing:-.05pt'>For</span><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi;letter-spacing:.05pt'> </span><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi;letter-spacing:-.1pt'>women</span><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi'> <b style='mso-bidi-font-weight:normal'>in<span
    style='letter-spacing:-.05pt'> their</span> <span style='letter-spacing:
    -.05pt'>60s</span> </b><span style='letter-spacing:-.1pt'>who</span> are<span
    style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>taking</span><span
    style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>Livial,</span>
    <span style='letter-spacing:-.05pt'>the</span> <span style='letter-spacing:
    -.05pt'>figure</span> <span style='letter-spacing:-.05pt'>would</span> be <b
    style='mso-bidi-font-weight:normal'><span style='letter-spacing:-.1pt'>24</span>
    in<span style='letter-spacing:-.15pt'> </span>1000<span style='letter-spacing:
    -.15pt'> </span></b><span style='letter-spacing:-.05pt'>(i.e.</span><span
    style='letter-spacing:-.15pt'> </span>an <span style='letter-spacing:-.05pt'>extra</span><span
    style='letter-spacing:-.1pt'> </span>13<span style='letter-spacing:3.25pt'>
    </span><span style='letter-spacing:-.05pt'>cases).</span></span><span
    style='font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="597" height="40" alt="Text Box: For women in their 60s who are taking Livial, the figure would be 24 in 1000 (i.e. an extra 13 cases)." src="file:///C:/Users/ajaj/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:442.8pt;height:25.8pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>2.6&nbsp; Other conditions</p><p><strong>&nbsp;</strong></p><p>HRT will not prevent memory loss. There is some evidence of a higher risk of memory loss in women who start using HRT after the age of 65. Speak to your doctor for advice.</p><p>Livial is not intended for contraceptive use.</p><p>Treatment with Livial results in a marked dose-dependent decrease in HDL cholesterol (from - 16.7% with a 1.25 mg dose to -21.8% for the 2.5 mg dose after 2 years). Total triglycerides and lipoprotein(a) levels were also reduced. The decrease in total cholesterol and VLDL-C levels was not dose-dependent. Levels of LDL-C were unchanged. The clinical implication of these findings is not yet known.</p><p>Oestrogens may cause fluid retention, and therefore patients with cardiac or renal dysfunction should be carefully observed.</p><p>Women with pre-existing hypertriglyceridaemia should be followed closely during oestrogen replacement or Hormone replacement therapy, since rare cases of large increases of plasma triglycerides leading to pancreatitis have been reported with oestrogen therapy in this condition.</p><p>Treatment with Livial results in a very minor decrease of thyroid binding globulin (TBG) and total T4. Levels of total T3 are unaltered. Livial decreases the level of sex-hormone-binding globulin (SHBG), whereas the levels of corticoid binding globulin (CBG) and circulating cortisol are unaffected.</p><p>&nbsp;</p><p>2.7&nbsp; Other medicines and Livial</p><p><strong>&nbsp;</strong></p><p>Some medicines may interfere with the effect of Livial. This might lead to irregular bleeding. This applies to the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines against <strong>blood clotting </strong>(such as warfarin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for <strong>epilepsy </strong>(such as phenobarbital, phenytoin and carbamazepine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for <strong>tuberculosis </strong>(such as rifampicin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Herbal remedies containing <strong>St John&rsquo;s Wort </strong>(Hypericum perforatum).</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, herbal medicines or other natural products.</p><p>&nbsp;</p><p>2.8&nbsp; &nbsp;Having an Operation</p><p><strong>&nbsp;</strong></p><p><strong>If you are going to have an operation</strong>, make sure your doctor knows about it. You may need to stop taking HRT about 4 to 6 weeks before the operation, to reduce the risk of a blood clot. Your doctor will tell you when you can start taking HRT again.</p><p>&nbsp;</p><p>2.9&nbsp; &nbsp;Livial with food and drink</p><p><strong>&nbsp;</strong></p><p>You can eat or drink normally while you are taking Livial.</p><p>&nbsp;</p><p>2.10&nbsp; &nbsp; &nbsp; Pregnancy and breast-feeding</p><p>&nbsp;</p><p>Livial is for use in postmenopausal women only. If you become pregnant, stop taking Livial and contact your doctor.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p>2.11&nbsp; &nbsp; &nbsp; &nbsp; Driving and using machines</p><p><strong>&nbsp;</strong></p><p>Livial has no known effect on the ability to drive or use machines.</p><p>&nbsp;</p><p>2.12&nbsp; &nbsp; Livial contains Lactose</p><p><strong>&nbsp;</strong></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before using Livial.</p><p>If you are worried about anything in this section, talk to your doctor about the risks and benefits of HRT.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><strong>3.1&nbsp;&nbsp;&nbsp; </strong><strong>When</strong><strong> </strong><strong>can you start taking Livial?</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:750px"><tbody><tr><td style="width:438px"><strong>If</strong><strong> </strong><strong>it</strong><strong> </strong><strong>is</strong><strong> not yet 12 months </strong>since your last natural period&hellip;</td><td style="width:311px"><p><strong>Wait before taking Livial</strong></p><p>(see Section 2.1)&hellip;</p></td></tr><tr><td style="width:438px">If you are changing over from a <strong>period free HRT</strong>&hellip;&nbsp; (see note below)&hellip;</td><td style="width:311px"><strong>Start taking Livial straight away</strong></td></tr><tr><td style="width:438px">If you have <strong>never used HRT before</strong></td><td style="width:311px"><strong>Start taking Livial straight away</strong></td></tr><tr><td style="width:438px">If you were prescribed HRT because you have had a <strong>hysterectomy</strong>&hellip;</td><td style="width:311px"><strong>Start taking Livial straight away</strong></td></tr><tr><td style="width:438px">If you are being treated for <strong>endometriosis </strong>(a condition in which parts of the womb lining move around the body)&hellip;</td><td style="width:311px"><strong>Start taking Livial straight away</strong></td></tr><tr><td style="width:438px"><p>If you are changing over from another type of HRT with which you have <strong>periods</strong>&hellip;</p><p>(see the note below)&hellip;</p></td><td style="width:311px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Wait for your next period</strong>. Start taking Livial as soon as your period ends</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>If</strong><strong> </strong><strong>you are changing over from another type of HRT&nbsp;</strong></p><p>There are several different types of HRT, such as tablets patches and gels. Most contain either oestrogen, or oestrogen and progestogen. With some you still have periods, and with some you don&rsquo;t <em>(these</em><em> are called period-free HRT)</em>.</p><p>&nbsp;</p><p>3.2&nbsp;&nbsp;&nbsp; How to take Livial</p><p>&nbsp;</p><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>The</strong><strong> recommended dose is one tablet every day. </strong>Take this dose unless your doctor or pharmacist told you to do something different.</p><p>&nbsp;</p><p>Press the tablet so that it comes through the foil. Swallow the tablet with some water or other drink, without chewing. <strong>Take Livial at the same time each day.</strong></p><p><strong>&nbsp;</strong></p><p>The strips of tablets are marked with the days of the week. Start by taking a tablet marked with the current day. For example, if it is Monday, take a tablet marked Monday on the top row of the strip. Follow the arrows until the strip is empty. Start the next strip the next day. Do not leave a break between strips or packs.</p><p>&nbsp;</p><p>Your doctor will aim to prescribe the lowest dose to treat your symptoms for as short as necessary. Speak to your doctor if you think this dose is too strong or not strong enough.</p><p>&nbsp;</p><p>3.3&nbsp;&nbsp;&nbsp; If you take more Livial than you should</p><p>It is unlikely that taking more than one tablet will do you any harm, but you may feel sick, be sick or have some vaginal bleeding.</p><p>&nbsp;</p><p>3.4&nbsp;&nbsp;&nbsp; If you forget to take Livial</p><p>If you forget to take a tablet, take it as soon as you remember, unless you are more than 12 hours late. If you are more than 12 hours late, just skip it, and take your next tablet at the usual time.</p><p>Don&#39;t take a double dose.</p><p><strong>&nbsp;</strong></p><p><strong>3.5&nbsp;&nbsp;&nbsp; </strong><strong>If</strong><strong> </strong><strong>you need to have surgery</strong></p><p>If you are going to have surgery, tell the surgeon that you are taking Livial. You may need to stop taking Livial about 4 to 6 weeks before the operation to reduce the risk of a blood clot (see section 2, &#39;Blood clots in a vein&#39;). Ask your doctor when you can start taking Livial again.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The following diseases are reported more often in women using HRT compared to women not using HRT:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ovarian cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots in the veins of the legs or lungs (venous thromboembolism)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; probable memory loss if HRT is started over the age of 65 For more information about these side effects, see section 2.</p><p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them<strong>.</strong><strong>&nbsp; Most side effects are mild.</strong></p><p><strong>&nbsp;</strong></p><p><strong>&rarr;Tell</strong><strong> </strong><strong>your</strong><strong> doctor or pharmacist </strong>if you are worried about any side effects which you think may be due to Livial. (see also section 2.3, &#39;Stop taking Livial and see a doctor immediately&#39;)</p><p>&nbsp;</p><p>&nbsp;</p><p>1.1&nbsp;&nbsp;&nbsp; Serious side effects &ndash; see a doctor straight away</p><p><strong>&nbsp;</strong></p><p><strong>If</strong><strong> </strong><strong>you think you may have signs of a serious side effect, see a doctor straight away.</strong></p><p>You may need to stop taking Livial:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your <strong>blood pressure </strong>rises</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your skin or the whites of your eyes go yellow (<strong>jaundice</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suddenly have <strong>migraine</strong>-type headaches (see section 2.5 above)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have signs of a <strong>blood clot </strong>(see section 2.5 above)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get any of the problems listed in section 2.1 (Do not take Livial)</p><p>&nbsp;</p><p>1.2&nbsp;&nbsp;&nbsp; Other side effects</p><p><strong>&nbsp;</strong></p><p><strong>Common </strong>(may affect up to 1 in 10 women):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach or pelvic pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual hair growth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaginal bleeding or spotting.</p><p>This is usually nothing to worry about in the first few months of taking HRT. If bleeding continues, or starts after you have been on HRT for a while See Section 2.4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaginal problems such as more secretions, itching, irritation and thrush</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thickening of the lining of the womb or the lining of the cervix</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 women):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen hands, ankles or feet &ndash; a sign of fluid retention</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach upset</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful nipples or breasts feeling uncomfortable</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaginal infections</p><p>&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1000 women):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy skin</p><p>&nbsp;</p><p>Some women taking Livial have also reported:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression, dizziness, headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain or muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin problems such as rash or itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of vision or blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in liver tests</p><p>There have been reports of breast cancer and of an increased cell growth or cancer of the lining of the womb in women using Livial.</p><p>&nbsp;</p><p>&rarr;Tell your doctor if any of the above mentioned side effects continues or becomes troublesome.</p><p>&nbsp;</p><p>The following side effects have been reported with other HRTs:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gall bladder disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; various skin disorders:</p><p>&nbsp;</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discolouration of the skin especially of the face or neck known as &ldquo;pregnancy patches&rdquo; (chloasma)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful reddish skin nodules (erythema nodosum)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash with target-shaped reddening or sores (erythema multiforme)</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via (The National Pharmacovigilance and Drug Safety Centre (NPC), SFDA) . By reporting side affects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton after &lsquo;EXP&rsquo;. The expiry date &nbsp;is written on outer pack &amp; inner label.</p><p>&nbsp;</p><p>&nbsp;</p><p>Store below 25&deg;C. Do not refrigerate. Store in the original package. Keep the blister in the outer carton, in order to protect from light and moisture.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Livial contains</p><p>The active substance is <strong>tibolone.</strong></p><p>The other ingredients are potato starch, lactose monohydrate, ascorbyl palmitate and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Livial looks like and the contents of the pack
Livial tablets are white, and marked Organon* on one side, and “MK2” on the other side. They come in packs of one or three strips of 28 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>N.V. Organon, Kloosterstraat 6, 5349 AB Oss, The Netherlands.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was revised in Sep 2020. 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ليفيال&nbsp; أقراص 2.5 ملغم.</p><p dir="RTL">المادة الفعالة: تيبولون</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليفيال علاج تعويضي هورموني، يحتوي على &quot;تيبولون&quot;، وهي مادة تؤثر إيجابيًّا على الأنسجة المختلفة في الجسم، مثل الدماغ، والمهبل، والعظام. يُستخدَم هذا الدواء للمرأة في سن اليأس التي لم تأتِها عادة شهريّة طبيعيّة منذ 12 شهرًا على الأقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُستخدَم ليفيال:</strong></p><p dir="RTL"><strong>للتخفيف من الأعراض بعد سن اليأس</strong></p><p dir="RTL">خلال مرحلة سن اليأس، تنخفض كميّة الإستروجين التي يُنتجها جسم المرأة بشكل حاد، ممّا قد يُسبّب أعراضًا، مثل الشعور بالحرارة على الوجه والعنق وفي الصدر (&quot;الهبّات الساخنة&quot;). يُخفّف ليفيال من هذه الأعراض بعد بلوغ سن اليأس. ولا يوصف لكِ إلا في حال عرقلت هذه الأعراض حياتك اليوميّة بشكل جدّي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الوقاية من مرض هشاشة العظام </strong></p><p dir="RTL">بعد انقطاع الطمث قد تُصاب بعض النساء بهشاشة العظام (ترقق العظام). يجب عليك مناقشة جميع الخيارات المتاحة مع طبيبك.</p><p dir="RTL">إذا كنتِ في خطر متزايد للكسور بسبب ترقق العظام، والأدوية الأخرى غير مناسبة لك، يمكنك استخدام ليفيال لمنع مرض هشاشة العظام بعد انقطاع الطمث.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هناك ثلاثة أنواع مختلفة من العلاج التعويضي الهورموني:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج التعويضي الهورموني بالإستروجين فقط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج التعويضي الهورموني المُركب، والذي يحتوي على نوعين من الهرمونات الأنثوية والاستروجين والبروجستيرون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليفيال الذي يحتوي على المادة الفعالة تيبولون.</p><p dir="RTL">ليفيال يختلف عن سائر العلاج التعويضي الهورموني. يحتوي على تيبولون &nbsp;بدلًا من الهرمونات الفعلية (مثل الإستروجين والبروجسترون). الجسم يقوم بتكسير تيبولون لصُنع الهرمونات. الآثار والفوائد مماثلة للعلاج التعويضي الهورموني.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في البند 6، &quot;محتوى العبوة ومعلومات أخرى&quot; يمكنك العثور مزيد من المعلومات حول ليفيال وما هي دواعي استخدامه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما يجب معرفته قبل استخدام ليفيال</strong></p><p dir="RTL">للحصول على معلومات حول البدء في تناول ليفيال، (بما في ذلك بعد استئصال الرحم) انظر البند 3-1</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التاريخ الطبي والمراجعات المنتظمة</strong></p><p dir="RTL">من الأهميّة قياس مخاطر العلاج التعويضي الهورموني أو ليفيال مقابل منافعه قبل البدء بتناوله أو اتخاذ القرار بمواصلة تناوله. وهذا مهم بشكل خاص إذا كنت أكثر من 60 &nbsp;عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تُعتبر تجربة الدواء لدى النساء اللواتي بلغن سن اليأس في وقت مُبكر (بسبب عمليّة جراحيّة أو بسبب قصور في المُبيضَيْن) محدودة. في حال إصابتك بسن اليأس في وقت مبكر، قد تختلف مخاطر استخدام ليفيال أو العلاج التعويضي الهورموني. لذا، يُرجى مناقشة ذلك مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل البدء بتناول ليفيال أو أي علاج تعويضي هورموني (أو إعادة البدء بتناوله)</strong></p><p dir="RTL">سيسألك الطبيب عن سيرتك الطبيّة وعن سيرة عائلتك الطبيّة. قد يُقرّر طبيبك إجراء فحص طبي جسدي، قد يشمل فحص الثديَيْن و/أو فحصًا داخليًّا، عند الضرورة.</p><p dir="RTL">&Ntilde;<strong> </strong><strong>&nbsp;أبلغي طبيبكِ</strong> إذا كانت لديكِ أي مشاكل صحية أو أمراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الفحوصات المنتظمة</strong></p><p dir="RTL">حين البدء بتناول ليفيال، عليكِ رؤية طبيبكِ من أجل إجراء مراجعات منتظمة (مرّة واحدة في السنة على الأقل). خلال هذه المراجعات، يمكنك مناقشة المنافع والمخاطر المرتبطة بمواصلة العلاج بواسطة ليفيال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما يوصي طبيبك بإجراء صورة إشعاعيّة للثديَيْن بشكل منتَظم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تأكدي من</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عمل فحوصات للثدي ومسحة عنق الرحم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفحص ثدييك بانتظام لأي تغييرات مثل تجوف الجلد، تغيرات في الحلمة، أو أي كتل يمكنك أن تريها أو تشعري بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>2_1 بعض النساء لا يجب أن تتناول ليفيال</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتناولي ليفيال</strong></p><p dir="RTL">لا تتناولي ليفيال اذا كانت إحدى الأعراض أدناه تنطبق عليك، أو في حال لم تكوني متأكّدةً من أيّ من النقاط أدناه، <strong>يُرجى التحدّث إلى طبيبكِ</strong> قبل المباشرة بالعلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مُصابة <strong>بسرطان الثدي</strong>، سواءً في الماضي أو في الحاضر، أو في حال الإشتباه بإصابتكِ به.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مُصابة <strong>بورمٍ خبيثٍ يتأثر بالإستروجين</strong> (مثل سرطان بطانة الرحم) وفي حال الاشتباه بأنّكِ مُصابة به.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابة بأي <strong>نزيف مهبلي غير مُبرّر</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديكِ <strong>سماكة مفرطة في بطانة الرحم</strong> (فرط تنسّج بطانة الرحم) لم تتمّ معالجتها بعد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابة، في الماضي أو في الحاضر، <strong>بجلطة دمويّة في أحد الأوردة</strong> (تخثّر)، &nbsp;مثلًا في الساقَيْن (تخثّر دموي عميق) أو في الرئتَيْن (انصمام رئوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مُصابة <strong>باضطراب في تجلّط الدم</strong> (مثل بروتيين سي، بروتيين آس، أو قصور في مُضاد الثرومبين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت، في الحاضر أو مؤخّرًا، بحالة سببها جلطات دمويّة في الشرايين، مثل <strong>نوبة قلبيّة</strong>، أو <strong>سكتة دماغيّة</strong>، أو <strong>ذبحة صدريّة</strong> (ألم حاد في الصدر بسبب قصور في الأكسجين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت، في الماضي أو في الحاضر، <strong>بمرض في الكبد</strong> وإذا لم تعُد فحوصات وظيفة كبدك إلى مستوى طبيعي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مُصابة بمرضٍ وراثي في إنتاج الصبغة الحمراء في الدم (بورفيريا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك <strong>حساسيّة من أيّ من مكوّنات هذا الدواء</strong>. هذه المكوّنات مُدرجة في البند 6.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ <strong>&nbsp;حاملًا</strong> أو تظنيّن أنّك حامل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ <strong>&nbsp;مرضعًا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال ظهور أي من الحالات الواردة أعلاه للمرّة الأولى وأنت تتناولين هذا الدواء، توقّفي عن تناوله على الفور واستشيري الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا بدأتي بمرحلة إنقطاع الطمث، يجب أن لا تتناولي ليفيال إلا بعد 12 شهرًا بعد أخر دوره شهرية. إذا تناولته &nbsp;مبكرًا، فقد يحدث لديك نزيف غير منتظم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>2_2 المحاذير والاحتياطات</strong></p><p dir="RTL">تحدثي مع طبيبك أو الصيدلي أو الممرضة قبل تناول ليفيال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل البدء بالعلاج، أطلعي الطبيب إذا كنت قد تعرّضت في الماضي لأيّ من الحالات التالية، بما أنّها قد تُعاودك أو قد تزداد سوءًا خلال العلاج بواسطة هذا الدواء. في هذه الحالة، عليك مراجعة طبيبك بتكرار أعلى لإجراء مراجعات طبيّة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم حميد في الرحم (أورام ليفيّة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة غير طبيعيّة حيث تكون بطانة الرحم في مناطق خارج الرحم أيضًا (الانتباذ البطاني الرحمي) أو نمو غير طبيعي لبطانة الرحم (فرط تنسّج بطانة الرحم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خطر التعرّض لجلطات دمويّة (راجع &quot;الجلطات الدمويّة في وريد (التخثّر))</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خطر الإصابة بسرطان يتأثّر بالإستروجين (مثلاً، أن يكون لديك أم أو أخت أو جدة أُصيبت بسرطان الثدي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب كبدي، مثل ورم كبدي حميد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصاة في المرارة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع النصفي أو حالات صُداع حادة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ذئبة حماميّة مجموعيّة (وهو مرض يُصيب جهاز المناعة قد يُصيب مناطقَ عديدة من الجسم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء الصرع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء الربو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض يؤثر على طبلة الأذن و السمع<strong> </strong>(تصلّب الأذن الوسطى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرتفاع مستوى الدهون في الدم (الدهون الثلاثية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس السوائل بسبب مشاكل قلبيّة أو كلويّة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>2_3 توقّفي عن تناول ليفيال وراجعي الطبيب فورًا</strong><strong> في الحالات التالية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في أي من الحالات المذكورة في قسم &quot;لا تتناولي ليفيال&quot;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصفرار البشرة أو بياض العينَيْن (اليرقان)، ممّا قد يُشير إلى الإصابة بمرض كبدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرتفاع حاد في ضغط الدم (قد تشمل الأعراض الصداع، أو الوهن، والدوخة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات صداع شبيهة بالصداع النصفي تحدث للمرة الأولى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أصبحتِ &nbsp;حاملًا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاحظتِ علامات تُشير إلى الإصابة بجلطة دمويّة، مثل:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ مؤلم وإحمرار الساقَيْن</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم مُفاجئ في الصدر</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفّس</p><p dir="RTL">للحصول على المزيد من المعلومات، يُرجى مراجعة &quot;جلطات الدم في الأوردة&quot; (التخثّر).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ملاحظة:</strong> &quot;ليفيال&quot; غير مانع للحمل. في حال مرور أقلّ من 12 شهرًا منذ عادتك الشهريّة الأخيرة أو في حال كنت دون 50 عامًا، قد لا تزالين بحاجة إلى استخدام أدوية مانعة للحمل لمنع الحمل. &nbsp;استشيري الطبيب للحصول على المشورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>2_4 العلاج التعويضي الهورموني والسرطان</strong></p><p dir="RTL"><strong>النمو غير الطبيعي لبطّانة الرحم (فرط تنسّج بطانة الرحم) وسرطان بطانة الرحم </strong></p><p dir="RTL">صدرت دراسات وتقارير للنمو غير الطبيعي لبطانة الرحم أو سرطان بطانة الرحم في النساء اللواتي يتناولن ليفيال. يزداد خطر سرطان بطانة الرحم مع ازدياد فترة الإستعمال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النزيف غير المنتظِم</strong></p><p dir="RTL">قد تتعرّضين لنزيف غير منتظَم أو تظهر قطرات دم (&quot;التبقيع&quot;) خلال الأشهر الثلاثة &nbsp;أو الستة الأولى لتناول ليفيال.</p><p dir="RTL">لكن، في حال:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استمرار النزيف غير المنتظِم لأكثر من الأشهر الستة الأولى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدء النزيف غير المنتظِم بعد تناول ليفيال لأكثر من 6 أشهر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استمرار النزيف غير المنتظِم بعد التوقّف عن تناول ليفيال</p><p dir="RTL"><strong>&Ntilde;</strong><strong> </strong><strong>راجعي الطبيب في أسرع وقتٍ ممكن.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سرطان الثدي</strong></p><p dir="RTL">تظهر الأدلة أن تناول تيبولون يزيد من خطر الإصابة بسرطان الثدي. خطر إضافي يعتمد على المدة التي تستخدمي فيها تيبولون. في الدراسات مع العلاج التعويضي الهرموني ، انخفض الخطر مع مرور الوقت بعد وقف العلاج التعويضي الهرموني ، ولكن قد تستمر المخاطر لمدة 10 سنوات أو أكثر عندما استخدمت النساء العلاج التعويضي الهرموني لأكثر من 5 سنوات. لا تتوفر بيانات عن استمرار المخاطر بعد التوقف عن تيبولون ، ولكن لا يمكن استبعاد نمط مماثل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المقارنة</strong></p><p dir="RTL">النساء اللواتي يتناولن ليفيال عرضة بنسبة أقل لسرطان الثدي مقارنةً مع النساء اللواتي يستخدمن علاجًا تعويضيًّا هورمونيًّا و بنسبة خطر متساوية مع النساء اللواتي يستخدمن الإستروجين لوحده.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&nbsp;افحصي ثديَيك بشكل منتظم. راجعي الطبيب في حال لاحظت أي تغييرات، مثل:</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نقرة علي البشرة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيّرات في الحلمة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي تكتّلات قد ترينها أو تشعرين بها</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&Ntilde;</strong><strong> </strong><strong>تحديد موعد لرؤية الطبيب في أقرب وقت ممكن</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>سرطان المبيض</strong></p><p dir="RTL">سرطان المبيض هو نادر - أندر بكثير من سرطان الثدي. ارتبط استخدام العلاج التعويضي بالهرمونات الإستروجين والبروجسترون أو الإستروجين فقط مع زيادة طفيفة في خطر الإصابة بسرطان المبيض.</p><p dir="RTL">خطر الإصابة بسرطان المبيض يختلف مع تقدم العمر. على سبيل المثال، في النساء اللواتي تتراوح أعمارهن بين 50-54 و لايتناولن علاج تعويضي هرموني، يتم تشخيص حوالي امرأتين من أصل 2000 امرأة بسرطان المبيض خلال فترة 5 سنوات. وبالنسبة للنساء اللواتي يتناولن علاج تعويضي هرموني لمدة 5 سنوات، سوف يكون هناك حوالي 3 حالات لكل 2000 امرأة (أي حوالي&nbsp; حالة واحدة إضافية).</p><p dir="RTL">يساوي الخطر المتزايد لسرطان المبيض مع تناول ليفيال، نسبة الإصابة عند استعمال أنواع أخرى من العلاج التعويضي الهورموني.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>2_5 أثر العلاج التعويضي الهورموني على القلب والدورة الدمويّة</strong></p><p dir="RTL"><strong>الجلطات الدمويّة في الأوردة (التخثّر)</strong></p><p dir="RTL">خطر التعرّض <strong>للجلطات الدمويّة في الأوردة</strong> أعلى بنسبة 1.3 إلى 3 أضعاف بالنسبة إلى النساء اللواتي يتناولن علاجًا تعويضيًّا هورمونيًّا مقارنةً مع اللواتي لا يتناولن العلاج، لا سيّما خلال العام الأول من العلاج.</p><p dir="RTL">يُمكن أن تكون الجلطة الدمويّة خطيرة. وفي حال انتقالها إلى الرئتَيْن، قد تُسبّب ألما في الصدر، أو انقطاع النفس، أو الإغماء، أو حتى الوفاة.</p><p dir="RTL">يزداد خطر التعرّض لجلطة دمويّة مع التقدّم في السن وفي حال انطباق أي من الحالات التالية عليك.</p><p dir="RTL">يُرجى الاتصال بالطبيب في الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنّك حاملٌ أو أنجبتِ طفلًا مُؤخَّرًا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناولين الإستروجين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنّكِ عاجزة عن المشي لفترة زمنيّة طويلة بسبب الخضوع لعمليّة جراحيّة، أو التعرّض لإصابة، أو مرض (راجعي أيضًا البند 3، &quot;إذا كنتِ تحتاجين للخضوع إلى عمليّة جراحيّة&quot;)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنّك تُعانين سمنة مفرطة (مؤشّر كتلة الجسم يتجاوز 30 كلغ/متر مربّع)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنّك مُصابة باضطراب جلطات الدم الذي يحتاج إلى علاج طويل الأمد بواسطة أدوية للوقاية من الجلطات الدمويّة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أصيب أحد أقاربك المقرّبين بجلطة دمويّة في الساق، أو الرئة، أو في أي عضو آخر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنّك مُصابة بذئبة حمائيّة مجموعيّة (SLE)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنّك مصابة بداء السرطان</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإطلاع على علامات الجلطة الدمويّة، راجعي &quot;توقّفي عن تناول ليفيال وراجعي الطبيب فورًا&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المقارنة</strong></p><p dir="RTL">بالنسبة إلى النساء في عقدهنّ الخامس اللواتي لا يتناولن علاجًا تعويضيًّا هورمونيًّا لفترة 5 أعوام، ستُصاب 4 إلى 7 نساء من أصل 1000 امرأة بجلطة دمويّة في الوريد.</p><p dir="RTL">بالنسبة إلى النساء في عقدهنّ الخامس اللواتي يتناولن علاجًا تعويضيًّا هورمونيًّا مختلطًا من الإستروجين والبروجستيرون لفترة 5 أعوام، ستُصاب 9 إلى 12 امرأة من أصل 1000 امرأة (أي 5 حالات إضافيّة لكل 1000 امرأة).</p><p dir="RTL">مع استخدام ليفيال، يُعتبر الخطر المتزايد للإصابة بجلطة دمويّة في وريد ما أدنى مقارنةً مع أنواع أخرى من العلاج التعويضي الهورموني.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;أمراض القلب (النوبة القلبيّة)</strong></p><p dir="RTL">لا أدلّة تُشير إلى أن العلاج التعويضي الهورموني أو ليفيال يقي من النوبة القلبيّة.</p><p dir="RTL">تُعتبر النساء اللواتي تجاوز عمرهنّ 60 عامًا ويتناولن علاجًا تعويضيًّا هورمونيًّا مختلطًا من الإستروجين والبروجستيرون أكثر عرضةً بقليل للتعرض لأمراض القلب مقارنةً مع اللواتي لا يتناولن أي علاج تعويضي هورموني. وبما أن خطر الإصابة بأمراض القلب يعتمد بشكل كبير على العمر، يُعتبر عدد الحالات الإضافيّة لأمراض القلب بسبب استخدام العلاج التعويضي الهورموني من الإستروجين والبروجسترون منخفضًا جدًّا لدى النساء في صحّة جيّدة قُبيل بلوغ سن اليأس، إنّما يزداد مع التقدّم في السن.</p><p dir="RTL">لا وجود لأدلّة تُشير إلى أن خطر الإصابة بنوبة قلبيّة عند تناول ليفيال يختلف عن الخطر المرتبط بأنواع أخرى من العلاج التعويضي الهورموني.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>السكتة الدماغيّة</strong></p><p dir="RTL">تُشير الأبحاث الأخيرة إلى أن ليفيال والعلاج التعويضي الهورموني يزيدان من خطر التعرّض لسكتة دماغيّة. وقد تمّت ملاحظة هذا الخطر المتزايد بشكل أساسي لدى النساء المسنّات بعد بلوغهنّ سنّ اليأس اللواتي تتجاوز أعمارهنّ 60 عامًا. العوامل الأخرى التي يمكن أن تزيد من خطر الإصابة بالسكتة الدماغية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقدم في السن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم كبار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التدخين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرب الكثير من الكحول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات قلب</p><p dir="RTL"><strong>&nbsp;إذا كنتِ قلقة بشأن أي من هذه الأمور</strong>، تحدثي مع طبيبكِ لمعرفة إذا كان يجب أن تأخذي العلاج التعويضي الهورموني</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المقارنة</strong></p><p dir="RTL">بالنسبة إلى النساء في عقدهنّ الخامس اللواتي لا يتناولن ليفيال لفترة 5 أعوام، يُصاب معدّل 3 نساء من أصل 1000 بسكتة دماغيّة. وبالنسبة إلى النساء في عقدهنّ الخامس اللواتي يتناولن ليفيال لفترة 5 أعوام، سيُصاب مُعدَّل 7 نساء من أصل 1000 امرأة بسكتة دماغيّة (أي 4 حالات إضافيّة لكل 1000 امرأة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة إلى النساء في عقدهنّ السادس اللواتي لم يتناولن ليفيال لفترة 5 أعوام، يُصاب معدّل 11 امرأة من أصل 1000 بسكتة دماغيّة. وبالنسبة إلى النساء في عقدهنّ السادس اللواتي يتناولن ليفيال لفترة 5 أعوام، ستُصاب 24 امرأة من أصل 1000 امرأة بسكتة دماغيّة (أي 13 حالة إضافيّة لكل 1000 امرأة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>2_6 حالات أخرى</strong></p><p dir="RTL">لا يقي العلاج التعويضي الهورموني من فقدان الذاكرة. تُشير بعض الأدلّة إلى وجود خطر أعلى لفقدان الذاكرة لدى النساء اللواتي بدأن بتناول علاج تعويضي هورموني بعد بلوغهنّ سنّ الـ65. &nbsp;اِتّصلي بطبيبك للحصول على المشورة.</p><p dir="RTL">ليفيال لا يستخدم كمانع للحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نتج عن العلاج باستخدام ليفيال انخفاض ملحوظ في الكوليسترول عالي الكثافة (من-16.7% بجرعة 1.25 ملغم إلى-21.8% للجرعة 2.5 ملغم بعد سنتين). كما انخفض مجموع الدهون الثلاثية ومستويات البروتينات الدهنية. الانخفاض في نسبة الكولسترول في الدم ومستويات الكوليسترول منخفض الكثافة لم تعتمد على الجرعة. و لم تتغير مستويات الكولسترول عالي الكثافة. لم يُعرف بعد أثر هذه النتائج السريرية.</p><p dir="RTL">قد تُسبب الاستروجينات احتباس السوائل، ولذلك يجب متابعة االمرضى الذين يعانون من اختلال وظيفي في القلب أو الكلي عن كثب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب متابعة الإناث الذين يعانون من مع إرتفاع الكوليسترول عن كثب أثناء استبدال الإستروجين أو العلاج بالهرمونات البديلة، حيث أُبلغ عن حالات نادرة عن إرتفاع الدهون الثلاثية في الدم مما يؤدي إلى التهاب البنكرياس أثناء العلاج بالإستروجين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">العلاج بإستخدام ليفيال ينتج عنه انخفاض طفيف &nbsp;جدًّا في البروتين الدرقي الرابط &nbsp;ومجموع رباعي يودوثيرونين. مستويات ثلاثي يودوثيرونين لم تغيير. ليفيال يقلل من مستوى غلوبولين مرتبط بالستيرويد القشري و هرمون الكورتيزول لم يتغير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>2_7 أدوية أخرى وليفيال</strong></p><p dir="RTL">قد تتداخل بعض الأدوية مع مفعول ليفال، ممّا قد يُسبّب نزيفًا غير منتظم. ينطبق ذلك على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية للوقاية من <strong>الجلطات الدمويّة</strong> (مثل وارفارين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية <strong>لداء الصرع</strong> (الفينوباربيتال، والفينيتوين، والكاربامازيبين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة <strong>لداء السل</strong> (مثل ريفامبيسين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاجات العشبيّة التي تحتوي على <strong>نبتة سانت جونز</strong> ((Hypericum perforatum</p><p dir="RTL">اطلعي الطبيب أو الصيدلي إذا كنتِ تتناولين أو تناولتِ مؤخّرًا أو قد تتناولين أي أدوية أخرى. يشمل ذلك الأدوية التي يُمكن الحصول عليها من دون وصفة طبيّة، بالإضافة إلى الأدوية العشبيّة أو العلاجات الطبيعيّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>2-8 الخضوع لعملية جرحية</strong></p><p dir="RTL">إذا كنتِ ستخضعين لعملية جراحية ، تأكدي من أن طبيبك على علم بذلك. قد تحتاجين إلى التوقف عن تناول العلاج التعويضي الهورموني مدة 4 إلى 6 أسابيع قبل العملية، للحد من خطر تجلط الدم. سوف يخبركِ طبيبكِ متى يمكن البدء بتناول العلاج التعويضي الهورموني مرة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>2_9 ليفيال مع الطعام والسوائل</strong></p><p dir="RTL">يُمكن الأكل والشرب بشكل عادي بينما تتناولين ليفيال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>2_10 الحمل والرضاعة</strong></p><p dir="RTL">يُستخدَم ليفيال لدى النساء اللواتي تجاوزن سنّ اليأس فحسب. في حال أصبحتِ &nbsp;حاملًا، توقّفي عن تناول ليفيال على الفور واتّصلي بطبيبك.</p><p dir="RTL">إذا كنت حامل أو مرضع، تعتقدي بأنك قد تكون حامل أو تخططي لإنجاب طفل، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>2_11 القيادة واستخدام الآليّات</strong></p><p dir="RTL">ليفيال ليس له أي تأثير معروف على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>2_12 يحتوي ليفيال على اللاكتوز</strong></p><p dir="RTL">المرضى الذين يعانون من مشاكل تحمل الغالاكتوز، فقر اللاكتاز أو سوء إمتصاص &nbsp;الغلوكوز &ndash; الغالاكتوز،&nbsp; لا ينبغي لهؤلاء المرضى تناول هذا الدواء.</p><p dir="RTL">&nbsp;اتصلي بطبيبكِ قبل استخدام ليفيال&nbsp; إذا أخبركِ الطبيب بـأنكِ لا تتحملين بعض أنواع السكريات.</p><p dir="RTL">إذا كنتِ قلقة بشأن أي شيء في هذا البند، تحدثي مع طبيبك حول المخاطر والفوائد من العلاج التعويضي الهورموني.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>_1 متى يمكن البدء بإستخدام </strong><strong>ليفيال؟</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>لم يمر 12 شهرًا</strong> على آخر عادة شهريّة</p></td><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;انتظري قبل تناول ليفيال</strong> ( إنظري البند 2_1)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا كنتِ تقومِين بالتغيير <strong>من فترة خالية من العلاج التعويضي الهورموني</strong>...&nbsp; (راجعي الملاحظة أدناه)</p></td><td rowspan="4"><p dir="RTL">إبدأي <strong>&nbsp;بتناول ليفيال &nbsp;فورًا</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا لم تستخدمي &nbsp;أبدًا <strong>العلاج التعويضي الهورموني</strong> من قبل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا تم وصف<strong> العلاج التعويضي الهورموني</strong> لأنكِ خضعتي لإزالة الرحم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا كنتِ تخضعين لعلاج التهاب بطانة الرحم (و هو تحرك أجزاء من بطانة الرحم في جميع أنحاء الجسم)...</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا كنتِ تقومين بتغيير من أي نوع آخر من العلاج التعويضي الهورموني أثناء <strong>الدورة الشهرية</strong>... (راجعي الملاحظة أدناه)...</p></td><td style="vertical-align:top"><p dir="RTL"><strong>انتظري للدورة الشهرية المقبلة.</strong> إبدأي &nbsp;بتناول ليفيال حالما تنتهي الدورة الشهرية</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنتِ تقومِين بتغيير من أي نوع آخر من &nbsp;العلاج التعويضي الهورموني</strong></p><p dir="RTL">هناك عدة أنواع مختلفة من العلاج التعويضي الهورموني مثل الرُقع و الحبوب والمواد الهلامية. ويتضمن معظمها إما الإستروجين، أو الإستروجين والبروجسترون. مع البعض لا يزال لديك دورة الشهرية ، ومع البعض الآخر لا يوجد دورة الشهرية (تسمى هذه الفترة الحرة من العلاج التعويضي الهورموني).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>_2 كيفية تناول ليفيال</strong></p><p dir="RTL">تناولي هذا الدواء &nbsp;دائمًا حسب إرشادات طبيبك أو الصيدلي استشيري طبيبك أو الصيدلي إذا لم تكوني متأكدة.</p><p dir="RTL">الجرعة الموصى بها قرص واحد كل يوم. تناولي هذه الجرعة كما هو محدد إلا إذا أخبرك طبيبك أو الصيدلي للقيام بشيء مختلف.</p><p dir="RTL">&nbsp;اضغطي على القرص ليخرج من الشريط. ابتلعي القرص مع بعض الماء أو المشروبات الأخرى، دون مضغ. تناولي ليفيال في نفس الوقت كل يوم.&nbsp;</p><p dir="RTL">أشرطة ليفيال مطبوعة عليها أيّام الأسبوع. إبدأي بتناول القرص المناسب لهذا اليوم. مثلاً، إذا كان اليوم يوم الاثنَيْن، تناولي القرص المطبوع عليه &quot;الاثنين&quot; في الصف الأعلى للشريط. من ثم، تابعي أيّام الأسبوع حتى انتهاء الشريط. وفي اليوم التالي لذلك، إبدأي بالشريط التالي . لا تتوقفي عن تناول الأقراص بين الأشرطة أو العبوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيصف الطبيب الجرعة الأدنى الممكنة لمعالجة أعراضك لأقصر فترة ممكنة. تحدّثي إلى الطبيب إذا كانت هذه الجرعة أعلى بكثير أو أدنى بكثير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>3_3 في حال تناولتِ جرعة زائدة من ليفيال</strong></p><p dir="RTL">من غير المرجح أن تناولت جرعة زائدة من ليفيال سيؤدي الى أي ضرر، ولكن قد تشعرِين بالمرض أو حدوث بعض النزيف المهبلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>3_4 في حال نسيتِ تناول ليفيال</strong></p><p dir="RTL">في حال نسيتِ تناول قرص ليفيال&nbsp; ، &nbsp;تناوليهْ في أسرع وقتٍ ممكنٍ، إلا في حال التأخّر لأكثر من 12 ساعة. في هذه الحالة، فوّتي القرص الذي نسيتِ. تناولي الجرعة التالية في الوقت المعتاد. لا تتناولي جرعةً مُضاعفةً للتعويض عن جرعة منسيّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>3_5 إذا كنتِ تحتاجين للخضوع إلى عمليّة جراحيّة</strong><strong> </strong></p><p dir="RTL">في حال كنتِ ستخضعين لعمليّة جراحيّة، أخبري الطبيب الجرّاح أنّك تتناولين ليفيال. قد تحتاجين إلى ايقافه لمدّة 4 إلى 6 أسابيع قبل الخضوع للعمليّة للحدّ من خطر التعرّض لجلطة دمويّة (راجعي البند 2 &quot;الجلطات الدمويّة في الأوردة&quot; (التخثّر). &nbsp;اسألي الطبيب متى يُمكنك البدء بتناول ليفيال مُجدّدًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تمّ الابلاغ عن وجود الحالات التالية بوتيرة أعلى لدى النساء اللواتي يتناولن علاجًا تعويضيًّا هورمونيًّا مقارنةً مع النساء اللواتي لا يتناولن العلاج:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الثدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النمو غير الطبيعي أو سرطان بطانة الرحم (سرطان أو فرط تنسّج بطانة الرحم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان المبيض</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطة دمويّة في وريد في الساقَيْن أو الرئتَيْن (التخثّر الوريدي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض قلبي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكتة دماغيّة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة المحتمل في حال بدء العلاج التعويضي الهورموني بعد سن الـ65.</p><p dir="RTL">للمزيد من المعلومات عن هذه الآثار الجانبية، إقرأي البند 2.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على غرار الأدوية كلّها، يُمكن أن يُسبّب هذا الدواء آثارًا جانبيّةً، وإن كان لا يُصاب الجميع بها. معظم الأعراض الجانبية هي خفيفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&Ntilde; أخبري طبيبك أو الصيدلي إذا كنتِ قلقة بشأن أي من الآثار الجانبية إذا إعتقدتي أنها بسبب ليفيال. (انظري أيضا البند 2-3، توقّفي عن تناول ليفيال وراجعي الطبيب فورًا في الحالات التالية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>4_1 أثار جانبية خطيرة &ndash; يرجى مراجعة الطبيب على الفور.</strong></p><p dir="RTL">إذا كنتِ تعتقدين بوجود دلائل على الآثار الجانبية الخطيرة، يرجى مراجعة الطبيب على الفور</p><p dir="RTL">قد تحتاجين إلى التوقف عن تناول ليفيال:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ارتفع ضغط دمك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت بشرتك أو بياض عينيك يميل إلى اللون الأصفر (اليرقان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشعرين فجأة بالصداع النصفي_ نوع من الصداع (راجعي البند 2 أعلاه)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك دلائل على وجود تجلط في الدم (راجعي البند 2 أعلاه)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدثت لك أي من المشاكل المدرجة في البند 2 أعلاه (لا تتناولي ليفيال)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>4_2 آثار جانبيّة أخرى</strong></p><p dir="RTL">الآثار الجانبيّة الشائعة (قد تصيب امرأة واحدة من أصل 10):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الثديَيْن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم في البطن أو الحوض</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نمو شعر غير طبيعي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التبقيع أو النزيف المهبلي، عادةً لا يدعو للقلق في الأشهر القليلة الأولى من تناول العلاج التعويضي الهرموني. ولكن إذا استمر النزيف، أو بدأ بعد مرور فترة من الوقت من تناول العلاج التعويضي الهرموني (&nbsp;&nbsp; إقرأي البند 2_4 ).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشاكل المهبليّة، مثل الإفرازات، والحكة، والتهيُّج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إكتساب الوزن</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثر جانبي غير شائع (قد يصيب امرأة واحدة من أصل 100 امرأة):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين، الكاحل أو القدم، عرض لإحتباس السوائل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حبّ الشباب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الحلمات أو عدم إرتياح في الثدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإلتهابات المهبلية</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثر جانبي نادر (قد يصيب امرأة واحدة من أصل 1000 امرأة):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;حكة في الجلد</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الآثار الجانبيّة الأخرى الملحوظة خلال المشاهدات السريريّة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة، والصداع، والاكتئاب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المفاصل والعضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض جلدية مثل الطفح الجلدي أو الحكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات البصريّة (مثل عدم وضوح الرؤية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيّرات في وظيفة الكبد</p><p dir="RTL">ظهرت حالات سرطان ثدي وأورام أو سرطان بطانيّة الرحم لدى النساء اللواتي يستخدمن ليفيال.</p><p dir="RTL">&Ntilde; اطلعي الطبيب أو الصيدلي بإستمرار أي من الآثار الجانبيّة بشكل كبير.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">تمّ الابلاغ عن الآثار الجانبيّة التالية عند استخدام علاجات تعويضيّة هورمونيّة أخرى:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض المرارة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات جلديّة مختلفة:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيّر لون البشرة، لا سيّما في الوجه أو العنق، ما يُعرف بـ&quot;قناع الحمل&quot; (الكلف)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقيدات حمراء مائلة إلى الأزرق مؤلمة (الحمامى العقديّة)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مع فقاعات أو لطخات (حمامى متعدّدة الأشكال)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبيّة</strong></p><p dir="RTL">في حال تعرّضت لأي آثار جانبيّة، تحدّثي إلى الطبيب أو الصيدلي. يشمل ذلك أي آثار جانبيّة محتملة غير مدرجة في هذه النشرة. يمكنك الإبلاغ عن الآثار الجانبية عن طريق &quot;المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء&quot;. من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال.</p><p dir="RTL">&nbsp;لا تستعملي الدواء إذا انتهت مدّة صلاحيته الواردة على العبوة بعد عبارة (EXP). تاريخ انتهاء الصلاحيّة مُدون على العلبة الخارجية والشريط الداخلي.</p><p dir="RTL">يحفظ في درجة حرارة أقل من ٢٥ درجة مئوية. لا يُبرد. يُحفظ في العبوة الأصلية لحمايته من الضوء والرطوبة .</p><p dir="RTL">لا تتخلّصي من الأدوية في المراحيض أو في نظام الصرف الصحي أو في النفايات المنزلية. اسألي الصيدلي عن كيفيّة التخلّص من الأدوية التي لم تعُد تستعملينها. فيتمّ التخلّص منها بطريقة مسؤولة ولا ينتهي بها الأمر في احداث تلوث البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي ليفيال</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعّالة هي تيبولون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: اللاكتوز أحادي الهيدرات، نشا البطاطا، بَالْميتاتُ الأَسْكُورْبيل، ستيرات المغنسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص ليفيال بيضاء اللون، مطبوع عليها &quot;MK2 &quot;من جهة و &quot; Organon*&quot; على الجهة الأخرى.</p><p dir="RTL">ليفيال متوفّر في عبوات من الكرتون تحتوي على شريط أو 3 أشرطة من 28 قرصًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إن. في. أورجانون، كلوسترسترات 6، ٥٣٤٩ اي بي اوس. هولندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمّت آخر مراجعة لهذه النشرة في سبتمبر 2020.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Livial® 2.5 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 2.5 mg of tibolone. Excipient(s) with known effect:
Each tablet contains approximately 86.8 mg lactose monohydrate. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
White, round and flat tablets with beveled edges and a diameter of 6 mm and coded “MK” above “2” on one side and “Organon” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of oestrogen deficiency symptoms in postmenopausal women, more than one year after menopause.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (See also section 5.1.)</p><p>For all women the decision to prescribe Livial should be based on an assessment of the individual patient&rsquo;s overall risks and, particularly in the over 60s, should include consideration of the risk of stroke (see sections 4.4 and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Posology</u></em></p><p>The dosage is one tablet per day. The tablets should be swallowed with some water or other drink, preferably at the same time every day.</p><p>For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used.</p><p>A separate progestogen should not be added with Livial treatment.</p><p>Starting Livial</p><p>Women experiencing a natural menopause should commence treatment with Livial at least 12 months after their last natural bleed. In case of a surgical menopause, treatment with Livial may commence immediately.</p><p>Women being treated with gonadotrophin releasing hormone (GnRH) analogues, for example, for endometriosis, may commence treatment with Livial immediately.</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_49" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='width:521.65pt;height:27.75pt;visibility:visible;
 mso-wrap-style:square;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".58pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:.6pt;margin-right:19.4pt;margin-bottom:
    0in;margin-left:5.35pt;margin-bottom:.0001pt'><span style='font-family:
    "Times New Roman",serif;mso-hansi-font-family:Calibri;mso-hansi-theme-font:
    minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi;
    letter-spacing:-.05pt'>Any</span><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi;letter-spacing:-.15pt'> </span><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi;letter-spacing:-.05pt'>irregular/unscheduled</span><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi;letter-spacing:-.15pt'> </span><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi;letter-spacing:-.05pt'>vaginal</span><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi;letter-spacing:.05pt'> </span><span style='font-family:"Times New Roman",serif;
    mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
    Arial;mso-bidi-theme-font:minor-bidi;letter-spacing:-.05pt'>bleeding,</span><span
    style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
    mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
    minor-bidi'> <span style='letter-spacing:-.05pt'>either</span><span
    style='letter-spacing:.05pt'> </span>on<span style='letter-spacing:-.25pt'>
    </span>or<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:
    -.05pt'>off</span><span style='letter-spacing:.05pt'> </span><span
    style='letter-spacing:-.1pt'>HRT,</span> <span style='letter-spacing:-.05pt'>should</span>
    <span style='letter-spacing:-.1pt'>be</span> <span style='letter-spacing:
    -.05pt'>investigated</span> <span style='letter-spacing:-.05pt'>to</span> <span
    style='letter-spacing:-.05pt'>exclude</span> <span style='letter-spacing:
    -.05pt'>malignancy</span><span style='letter-spacing:4.35pt'> </span><span
    style='letter-spacing:-.05pt'>before</span> <span style='letter-spacing:
    -.05pt'>starting</span><span style='letter-spacing:-.15pt'> </span><span
    style='letter-spacing:-.05pt'>Livial</span><span style='letter-spacing:
    -.1pt'> </span><span style='letter-spacing:-.05pt'>(see</span> <span
    style='letter-spacing:-.05pt'>section</span> <span style='letter-spacing:
    -.05pt'>4.3).</span></span><span style='font-family:"Times New Roman",serif;
    mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="700" height="41" alt="Text Box: Any irregular/unscheduled vaginal bleeding, either on or off HRT, should be investigated to exclude malignancy before starting Livial (see section 4.3)." src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:521.65pt;height:27.75pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>Switching from a sequential or continuous combined HRT preparation</p><p>If changing from a sequential HRT preparation, treatment with Livial should start the day following completion of the prior regimen. If changing from a continuous-combined HRT preparation, treatment can start at any time.</p><p>&nbsp;</p><p>Missed dose</p><p>A missed dose should be taken as soon as remembered, unless it is more than 12 hours overdue. In the latter case, the missed dose should be skipped and the next dose should be taken at the normal time. Missing a dose may increase the likelihood of breakthrough bleeding and spotting.</p><p><em><u>Older people</u></em></p><p>No dose adjustment is necessary for the elderly.</p><p style="text-indent:50px">&nbsp;</p><p><em><u>Paediatric</u></em><em><u> population</u></em></p><p>There is no relevant use of Lival in the paediatric population.</p><p><u>Method of administration</u></p><p>Oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Pregnancy and lactation
•	Known, past or suspected breast cancer – Livial increased the risk of breast cancer recurrence in a placebo controlled trial
•	Known or suspected oestrogen-dependent malignant tumours (e.g. endometrial cancer)
•	Undiagnosed genital bleeding
•	Untreated endometrial hyperplasia
•	Previous or current venous thromboembolism (deep venous thrombosis, pulmonary embolism)
•	Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency, see section 4.4)
•	Any history of arterial thromboembolic disease (e.g. angina, myocardial infarction, stroke or TIA)
•	Acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal
•	Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
•	Porphyria

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For the treatment of postmenopausal symptoms, Livial should only be initiated for symptoms that adversely affect quality of life. In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually and Livial should only be continued as long as the benefit outweighs the risk.</p><p>&nbsp;</p><p>The risks of stroke, breast cancer and, in women with an intact uterus, endometrial cancer (see below and section 4.8) for each woman should be carefully assessed, in the light of her individual risk factors and bearing in mind the frequency and characteristics of both cancers and stroke, in terms of their response to treatment, morbidity and mortality.</p><p>Evidence regarding the risks associated with HRT or tibolone in the treatment of premature menopause is limited. Due to the low level of absolute risk in younger women, however, the balance of benefits and risks for these women may be more favourable than in older women.</p><p><u>Medical examination/follow-up</u></p><p>&nbsp;</p><p>Before initiating or reinstituting HRT or tibolone, a complete personal and family medical history should be taken. Physical (including pelvic and breast) examination should be guided by this and by the contraindications and warnings for use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During treatment, periodic check-ups are recommended of a frequency and nature adapted to the individual woman. Women should be advised what changes in their breasts should be reported to their doctor or nurse (see &lsquo;Breast cancer&rsquo; below). Investigations, including appropriate imaging tools, e.g. mammography, should be carried out in accordance with currently accepted screening practices, modified to the clinical needs of the individual.</p><p><u>&nbsp;</u></p><p><u>Conditions which need supervision</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of the following conditions are present, have occurred previously, and/or have been aggravated during pregnancy or previous hormone treatment, the patient should be closely supervised. It should be taken into account that these conditions may recur or be aggravated during treatment with Livial, in particular:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leiomyoma (uterine fibroids) or endometriosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risk factors for thromboembolic disorders (see below)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risk factors for oestrogen dependent tumours, e.g. 1st degree heredity for breast cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver disorders (e.g. liver adenoma)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes mellitus with or without vascular involvement</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cholelithiasis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Migraine or (severe) headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic lupus erythematosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A history of endometrial hyperplasia (see below)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epilepsy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Otosclerosis</p><p><u>Reasons for immediate withdrawal of therapy:</u></p><p><u>Therapy should be discontinued in case a contraindication is discovered and in the following situations:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice or deterioration in liver function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Significant increase in blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New onset of migraine-type headache <u>Endometrial hyperplasia and carcinoma</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The available data from randomised controlled trials are conflicting; however, observational studies have consistently shown that women who are prescribed Livial in normal clinical practice are at an increased risk of having endometrial cancer diagnosed (see also section 4.8). In these studies risk increased with increasing duration of use. Tibolone increases endometrial wall thickness, as measured by transvaginal ultrasound.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Break-through bleeding and spotting may occur during the first months of treatment (see section 5.1). Women should be advised to report any break-through bleeding or spotting if it is still present after 6 months of treatment, if it starts beyond that time or if it continues after treatment has been discontinued. The woman should be referred for gynaecological investigation, which is likely to include endometrial biopsy to exclude endometrial malignancy.</p><p><u>Breast cancer</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Evidence with respect to breast cancer risk in association with tibolone is inconclusive. The Million Women Study (MWS) has identified a significant increase in the risk of breast cancer in association with use of the</p><p>2.5 mg dose. This risk became apparent within a few years of use and increased with duration of intake, returning to baseline within a few (at most five) years after stopping treatment, see section 4.8. These results could not be confirmed in a study using the General Practice Research Database (GPRD).</p><p><u>Ovarian cancer</u></p><p>Ovarian cancer is much rarer than breast cancer.</p><p>Epidemiological evidence from a large meta-analysis suggests a slightly increased risk in women taking oestrogen- only or combined oestrogen-progestagen HRT, which becomes apparent within 5 years of use and diminishes over time after stopping.</p><p>Some other studies including the Women&rsquo;s Health Initiative (WHI) trial suggest that the use of combined HRTs may be associated with a similar, or slightly smaller risk (see section 4.8).</p><p>In the Million Women Study it was shown that the relative risk for ovarian cancer with use of tibolone was similar to the risk associated with use of other types of HRT.</p><p><u>Venous thromboembolism</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oestrogen or oestrogen-progestogen HRT is associated with a 1.3-3 fold risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism. The occurrence of such an event is more likely in the first year of HRT than later (see section 4.8). In an epidemiological study using a UK</p><p>database, the risk of VTE in association with tibolone was lower than the risk associated with conventional HRT, but only a small proportion of women were current users of tibolone and a small increase in risk compared with non-use cannot be excluded.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with known thrombophilic states have an increased risk of VTE and HRT or tibolone may add to this risk. HRT is therefore contraindicated in these patients (see section 4.3).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Generally recognised risk factors for VTE include use of oestrogens, older age, major surgery, prolonged immobilisation, obesity (BMI &gt; 30 kg/m2), pregnancy/postpartum period, systemic lupus erythematosus (SLE), and cancer. There is no consensus about the possible role of varicose veins in VTE. As in all postoperative patients, prophylactic measures need to be considered to prevent VTE following surgery. If prolonged immobilisation is to follow elective surgery temporarily stopping HRT or tibolone 4 to 6 weeks earlier is recommended, if possible. Treatment should not be restarted until the woman is completely mobilised.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In women with no personal history of VTE but with a first degree relative with a history of thrombosis at young age, screening may be offered after careful counselling regarding its limitations (only a proportion of thrombophilic defects are identified by screening).&nbsp; If a thrombophilic defect is identified which segregates with thrombosis in family members or if the defect is &lsquo;severe&rsquo; (e.g, antithrombin, protein S, or protein C deficiencies or a combination of defects) HRT or tibolone is contraindicated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Women already on anticoagulant treatment require careful consideration of the benefit-risk of use of HRT or tibolone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If VTE develops after initiating therapy, the drug should be discontinued. Patients should be told to contact their doctors immediately when they are aware of a potential thromboembolic symptom (e.g. painful swelling of a leg, sudden pain in the chest, dyspnea).</p><p><u>Coronary artery disease (CAD)</u></p><p>There is no evidence from randomised controlled trials of protection against myocardial infarction in women with or without existing CAD who received combined oestrogen-progestogen or oestrogen-only HRT. In an epidemiological study using the GPRD no evidence was found of protection against myocardial infarction in postmenopausal women who received tibolone.</p><p><u>Ischaemic stroke</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tibolone increases the risk of ischaemic stroke from the first year of treatment (see section 4.8). The baseline risk of stroke is strongly age-dependent and so the effect of tibolone is greater with older age.</p><p><u>Other conditions</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Livial is not intended for contraceptive use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with Livial results in a marked dose-dependent decrease in HDL cholesterol (from -16.7% with a</p><p>1.25 mg dose to -21.8% for the 2.5 mg dose after 2 years). Total triglycerides and lipoprotein(a) levels were also reduced. The decrease in total cholesterol and VLDL-C levels was not dose-dependent. Levels of LDL-C were unchanged. The clinical implication of these findings is not yet known.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oestrogens may cause fluid retention, and therefore patients with cardiac or renal dysfunction should be carefully observed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Women with pre-existing hypertriglyceridaemia should be followed closely during oestrogen replacement or hormone replacement therapy, since rare cases of large increases of plasma triglycerides leading to pancreatitis have been reported with oestrogen therapy in this condition.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with Livial results in a very minor decrease of thyroid binding globulin (TBG) and total T4. Levels of total T3 are unaltered. Livial decreases the level of sex-hormone-binding globulin (SHBG), whereas the levels of corticoid binding globulin (CBG) and circulating cortisol are unaffected.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HRT does not improve cognitive function. There is some evidence of increased risk of probable dementia in women who start using continuous combined or oestrogen-only HRT after the age of 65.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since Livial may increase blood fibrinolytic activity, it may enhance the effect of anticoagulants. This effect has been demonstrated with warfarin. Caution should therefore be exercised during the simultaneous use of Livial and anticoagulants, especially when starting or stopping concurrent Livial treatment. If necessary, the dose of warfarin should be adjusted.</p><p>There is limited information regarding pharmacokinetic interactions with tibolone An <em>in vivo </em>study showed that simultaneous treatment of tibolone affects pharmacokinetics of the cytochrome P450 3A4 substrate midazolam to a moderate extent. Based on this, drug interactions with other CYP3A4 substrates might be expected.</p><p>Compounds that induce CYP3A4 activity such as barbiturates, carbamazepine, hydantoins and rifampicin may enhance the metabolism of tibolone and thus affect its therapeutic effect.</p><p>Herbal preparations containing St.John&rsquo;s wort (Hypericum Perforatum) may induce the metabolism of oestrogens and progestogens via CYP3A4. Clinically, an increased metabolism of oestrogens and progestogens may lead to decreased effect and changes in the uterine bleeding profile.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Livial is contraindicated during pregnancy (see section 4.3). If pregnancy occurs during medication with Livial, treatment should be withdrawn immediately. For Livial no clinical data on exposed pregnancies are available.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. <u>Breast-feeding</u></p><p>Livial is contraindicated during breast-feeding (see section 4.3).</p><p><u>Fertility</u></p><p>In animal studies, Livial had anti-fertility activities by virtue of its hormonal properties.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Livial is not known to have any effects on alertness and concentration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This section describes undesirable effects, which were registered in 21 placebo-controlled studies (including the LIFT study), with 4,079 women receiving therapeutic doses (1.25 or 2.5 mg) of Livial and 3,476 women receiving placebo. The duration of treatment in these studies ranged from 2 months to 4.5 years. Table 1 shows the undesirable effects that occurred statistically significantly more frequently during treatment with Livial than with placebo.</p><p><!--[if gte vml 1]><v:group id="Group_x0020_47" o:spid="_x0000_s1041"
 style='position:absolute;left:0;text-align:left;margin-left:78pt;margin-top:15.75pt;
 width:458.3pt;height:.1pt;z-index:-19744;mso-position-horizontal-relative:page'
 coordorigin="1560,315" coordsize="9166,2" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Freeform_x0020_48" o:spid="_x0000_s1042" style='position:absolute;
  left:1560;top:315;width:9166;height:2;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9166,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9166,e" filled="f" strokeweight=".20497mm">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;9166,0"
   o:connectangles="0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--></p><p>&nbsp;</p><p><strong><img width="850" height="525" alt="" src="data:image/png;base64,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" /></strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_44" o:spid="_x0000_s1038" style='width:458.9pt;height:.6pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9178,12" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:group id="Group_x0020_45" o:spid="_x0000_s1039" style='position:absolute;
  left:6;top:6;width:9166;height:2' coordorigin="6,6" coordsize="9166,2"
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:shape id="Freeform_x0020_46" o:spid="_x0000_s1040" style='position:absolute;
   left:6;top:6;width:9166;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9166,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9165,e" filled="f" strokeweight=".58pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;9165,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_24" o:spid="_x0000_s1026" style='width:459.6pt;height:.6pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9192,12" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:group id="Group_x0020_25" o:spid="_x0000_s1027" style='position:absolute;
  left:6;top:6;width:9180;height:2' coordorigin="6,6" coordsize="9180,2"
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="Freeform_x0020_26" o:spid="_x0000_s1028" style='position:absolute;
   left:6;top:6;width:9180;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9180,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9180,e" filled="f" strokeweight=".20497mm">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;9180,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="613" height="1" src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:459.6pt;height:.6pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><img width="834" height="158" alt="" src="data:image/png;base64,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" /></p><p>In market use, other undesirable effects that have been observed include:</p><p>dizziness, rash, seborrheic dermatosis, headache, migraine, visual disturbances (including blurred vision), depression, effects on the musculoskeletal system such as arthralgia or myalgia and changes in liver function parameters.</p><p><u>Breast cancer</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An up to 2-fold increased risk of having breast cancer diagnosed is reported in women taking combined oestrogen-progestogen therapy for more than 5 years.</p><p>Any increased risk in users of <em>oestrogen-only </em>and tibolone therapy is substantially lower than seen in users of</p><p><em>oestrogen-progestogen</em><em> </em>combinations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The level of risk is dependent on the duration of use (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Results of the largest epidemiological study (MWS) are presented.</p><p>&nbsp;</p><p><img width="795" height="297" alt="" src="data:image/png;base64,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" /></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" colspan="4"><p>.<u>Endometrial cancer risk</u></p><p><u>Postmenopausal women with a uterus</u></p></td></tr></tbody></table><p>The endometrial cancer risk is about 5 in every 1,000 women with a uterus not using HRT or tibolone.</p><p>&nbsp;</p><p>The randomised placebo controlled trial that included women who had not been screened for endometrial abnormalities at baseline, and therefore reflected clinical practice, identified the highest risk of endometrial cancer, (LIFT study, mean age 68 years). In this study, no cases of endometrial cancer were diagnosed in the placebo group (n=1,773) after 2.9 years compared with 4 cases of endometrial cancer in the Livial group (n=1,746). This corresponds to a diagnosis of 0.8 additional case of endometrial cancer in every 1,000 women who used Livial for one year in this study (see section 4.4).</p><p><u>Risk of ischaemic stroke</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The relative risk of ischaemic stroke is not dependent on age or on duration of use, but as the baseline risk is strongly age-dependent, the overall risk of ischaemic stroke in women who use HRT or tibolone will increase with age, see section 4.4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A 2.9 year randomised controlled study has estimated a 2.2-fold increase in the risk of stroke in women (mean age 68 years) who used 1.25 mg Livial (28/2,249) compared with placebo (13/2,257). The majority (80%) of strokes were ischaemic.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The baseline risk of stroke is strongly age-dependent. Thus, the baseline incidence over a 5 year period is estimated to be 3 per 1,000 women aged 50-59 years and 11 per 1,000 women aged 60-69 years.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For women who use Livial for 5 years, the number of additional cases would be expected to be about 4 per 1000 users aged 50-59 years and 13 per 1,000 users aged 60-69 years.</p><p>Other adverse reactions have been reported in association with oestrogen and oestrogen-progestogen treatment:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Ovarian cancer</p><p>Use of estrogen-only or combined oestrogen-progestogen HRT has been associated with a slightly increased risk of having ovarian cancer diagnosed (see section 4.4).</p><p>A meta-analysis from 52 epidemiological studies reported an increased risk of ovarian cancer in women currently using HRT compared to women who have never used HRT (RR 1.43, 95% CI 1.31-1.56). For women aged 50 to 54 years taking 5 years of HRT, this results in about 1 extra case per 2,000 users. In women aged 50 to 54 who are not taking HRT, about 2 women in 2,000 will be diagnosed with ovarian cancer over a 5-year period.</p><p>In the Million Women Study, taking 5 years of tibolone resulted in 1 extra case per 2,500 users (see section 4.4).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HRT is associated with a 1.3-3-fold increased relative risk of developing venous thromboembolism (VTE), i.e. deepvein thrombosis or pulmonary embolism. The occurrence of such an event is more likely in the first year of using HRT (see section 4.4). Results of the WHI studies are presented:</p><p>&nbsp;</p><p><img width="680" height="217" alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAqgAAADZCAYAAADsWcIRAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAFiUAABYlAUlSJPAAAGHbSURBVHhe7b3fixxHtu+r/0FP7behYR4uehAIgREcqIehHtyXOX7YuiAL6rB7YFrQZzMbH0+h2hcNdiMjhjKFddDdQhqK6dPIXM1IyfQcj5DouaUeBoNpKITBmL4FZjCi6cMg9oimMcaYZp1Y8SsjIiMyI6u6urOy1gcWdGflj/iRseKb8fMMEARBEARBEESFIIFKEARBEARBVAoSqARBEARBEESlIIFKEARBEARBVAoSqARBEARBEESlIIFKEARBEARBVAoSqARBEARBEESlIIFKEARBEARBVAoSqARBEARBEESlIIFKEARBEARBVAoSqARBEARBEESlIIFKEARBEARBVAoSqARBEARBEESlqJlAPYRhtwFnzpyJssXuEH6QV+bj3ncFkv3AlfsJtPR5i9BKXsofjpHDEWx1W7DAn7EAjfYGDPe/lz+eMFZ8lTWgO3zNflpxjgtL0/0lJK1FeZyl1cOH0F3Mno+G13w37MKi57czi134/PPAbzwsh/xpPo72h5DotDwDC60uJMN9ODoYwuCFc93RN5D0nsC+/Hd8fnDSxnxPXrN3bYkdOwet/pfszasi38NesgoLzT6MjuShQsy8RguVoXHTBsN0Hzb1PY/gcNiDBrvHQmsddg+jA3q8HKs/KPlu/DA0ytOUfBFytA/DpAutBfUsT/i8foJZK0nLkxVeNPaOvPw86BOyhmX9f8XXAeazZ5SjUR+ambgtQLO/y0rArPM97A/eZ2UY67gERqdVholTo4YC9W1o9T6Dff4um5Wd4aCZQ93pteBctEBFXsGgfUHeK0egMrdwMOhIwTOFSuFwB7qNBRkOw0qJhePlaC+BZV05XYb+6Dv5Cyb1FnR0eC9Ae/BK/qL4Dkb9G/Y1ptPNxMvMB/d+eK/L8rcIJ83TctFyfqlgdYXtAez2l5nYOb5KLY2n+W7uwaDTZMcqLFCPdqHfxDz15WceZv7klaGyacPE6O46E0jmPVXldsoC9Tj9wRjvhjcdjxUlmtkzsGxIIbqwnMCem+SW7wq9OyK9Flt3YAc/ulG0nmtBb4d9NPLfzQ+dNL+P9j+DXuvttMzqd9Q+j4OCer0NjZkXqGZ5MmyhA4OD03rfjxErD8v6GqIO1E6gvhgMmZRQBAQqwl7+jfUXJQSq2YqaX7n+oFv6jrtSeA0vkkfCcTOEUz4XFabpIlvUeDhY5dQeGHlgVtDubwx0Qks3bIdqtrZkKhEzH1wRmZPfGZRz97WwYqW7Yhw/gFHS4WLnWFtddDynJR6mQUF+5mLmT8H7Gp02TJyOEmhz4XOaZSDM9PxBBFN/xwzBWFg20lZtfr73o5qVvd4tSPZkj9APX8Hgr6Yw8QtU5Ii9B+u6zIbPE7DyP/h8tgXqwQDaS6fXMDF9ZKMAz8NZ8pHEcVHzMaixggUruW14ZHT1nmm0mbNTX+2IKYyWoT/4FLpSHC6or31JqEKyu5Ob0F7fkS2945J+QXtbLE4SdJaqFdX9gre67swWVqywbkOru2O3Bp2IQE3v4+YfR3Xx61YrGR5lLFwvrSEHWAl+Zzyf2WIXhka9eLS/A+ttea9GB5LBfVs8uF2cVty/h/1hot+5zPt5uAsJv7fsDtvbhv7mNBz6K5Yeb0PjkmrZsFvMbTDMG1I8YrgewoBVOOI6R1yMlTZpK6k+zu3/hFZLtbKjuc8yyyGGqw+DkZLZ5vvFbPF9SD434+B2NbKPl8HDNF/4OfaQmyiBasVPnKc/QBdWIfnms8C7YQp05lOSr2Bv8Ek61CEjUM0ygub7QEvJTSs3T7j5xKCJ2QOyxJ79Wh6XHGxDbz2v56NIeCoCLa2WiC3CKXOYvv2BzH83HY3nGP5LD2eyhkGY74jzvmG+yh6+hTPnYDn5JpAWzodiqwuPku2CbnBPmJWPKhVmyeEIBo/MoR1OnVb0TvOPEOPjH8v96GvmI545Ph/ruZVwC6rnOWZ87He8oLwU+VniRCGByhBd1KpL2Oiy0oUIMR1JEzqDPfvcRg+G0jl4KyTVvcXP+0G2JLBC74qzaFjB3uox54COowrjc4y0cBzr0egTaLfe1pVc2vWOldVKVuCciEB1WnOw27TLBJQWKiahViKzi01VgkYFbApU3b0pK2VL+BphNYW+KUKs90Wltarg5f/yHRSVwKWC+I8HdhkvtT+FHR3v0FAKI311uMzhHoa4mChtzDw3BYsphDzPUmXb/R+xuhZFWf9BD2Mx46t6DqRI1/GwPxijW1B1/Nh5jz6HFy++gh2ez7J70xd//sxF+V6wynXnjj3UISNQEfneNt6HgfthZhKTVsGyESKvBZ6Fa/1+Qff0BAKVf8QtOz4jRPr+irx0/8dzzBY+2xf9wM5d6mxJseaUV5WOus4w3tXWJzB88QWMduSzQj0UOB5+WQlnwxbM4RA+wmE+Gq3DcmyY1fN5K7jpSx1RnftO/11ep8q9FObWeyQEbLOgASY7lMV8z4x45paXIj9LnDQkUE3BwwubeY1ZgE1hlDrGtGCkY2SyFVIqZPTXqfrqG2e8UKbl4jhaYycnTQtmuvuOFfI+c7p7W2nlqn5D5+XrorK+fvNsEoGKmM5aGQp+s0UNCVXCPnFkvCdaoBpC1uzW9IkHM2/Vs7RgSuOr3jFRgcnwGZXT0d6n0Dv2FlR02G0hxkyx5HuHdZhNQedLrwnTxntPxFdejWfp69NjqRgw8lvlofHsTBnWcfRcx0+LFKjG/S4tP4KvWVrwMqUEoS/+Mp3SXgBnspgnHfmHQutmvjgdJ630eQWYHwDWh8EIkvUhy7k8jOdZ+e1inmea6zMC6DAaeaaPGeMhjbikacLSyRDa2i/qd0K9m+o+xrt66ReQfM3KF7/vhWALquVrXbM+IDx4w8wE3fansB0Z5vSdlh9nhs/W5QPJfae/lWX3XDpvxJqIimX7/bi6zfOep2E08jyvvOh0CflZ4qQhgcoKpv1lbF5jOjNfhcfwFMxMhWQ4hKzldZHmgN0vm/dlVwXeJ6876ISw4injpbvszBYt8fV8MLgBS77WNyNNs5WemQ9uZROT3y5uN54y86s5VAn7xJERPu3cA9d7nGrq0NNzcysjLuoMMcFbgp9Np0Xd+qBw89PpfvPFzZtek6WN/56Ip7x6K2bjel9+qWPeZ6sWFlX2PNcxygtUp5JX+MJgljn2gdLdGrGYG1jp+I3o3mwyEZQnYJBx0srMv1zMMetK3GOL131YL/SFxvOs/HbxnHf4JfTNiVQ5pGXOfLfTe6b5Y5Q99aHG0m69t52KVV02XVNx9/mMEmBXOxNZaV1gfhT6MFsXpZ8uG2a3Nd3w2X6B6n+nTd+20OrBlrcHKwKPv/AK1JzyUuxn5YnEiUECVcPcxGgA/fYytFo+ATSBQC2qeCbA6jaNriCmhen4sJvkc9jbfgibvDI0u4Gw0tuAR51b/tZjI02zcTougepOqMP8d8Yha6cUqoR94uj4BarX0brocWvyWj6ea0xn7wVFRQc6hhC1HLrrwH1x86bXZGnjvyfiKa/eclgQplyBqsBxqH1ot1rQUmXxpAQqw54s6Qz50enIjrfe0d2whasAjJNWmXTJwW2Bf/032Fz/zCiPIYznWfnt4j8vdgyqv8z545quYoIfKn+D15bQjhGfMedEYAyNKaxnlMDkfnoHDkbPYLNUmCUojvsdVmeqd8t5dtE7jQ0EvJtdnCPGhe7mv5s+PP4i5DdD5SXKzxInCglUxBqU/jWriNU15ovqqfAQowJQX62ZCsmsWI79SywVhZXohrAqnrdh+b5R6Zhfr3nh1WnKLFPpmfngOpLI/Oaw+/R6HoHMHKaaeKOdc6gS9lXYPuceuD5ShKXvU1HLCLYGqwk97PzQu2amr7a8yp7h5F3WnJ4AX9y86TVZ2vjviXjKqxGHtLL0tICZYVJ56H02ug5z0sfX2esYGX8QoqgyD4SBgz0quHQSf47xnuh0RCHyDHb0kJaCcXXjpJUbplxU6zOG5QK82+1Cz22F92I8L/edjTnvFWwnn3t9UPrxZfgYI01s32X0JjRvQLf70Ch35nsY6i3z+Ywx4f63yE8gZl6+Da32JyXDnApL3vPIRLryKeUEqsCaJBl8Zg4ef5ErOD3l5ftoP0ucFCRQTUfJnYN5TbFATR1ZWqiyFZLZHTpG4VPwr94LxjqvAvG8qgzktiseu+vX7DrydAsrTAGVqfTMfJhQoHab0NCTAgyUyD62FlQj3kYFlL47hkP0iRBT9HtF50vY7H2aTiJQrSOTVnYa/AjyDccwu2qdSrtI4OhyMGHaePMA8ZVX41n6+vS8NPyRAlW3Qqk4eq5jTFWg7j+Bnh7ak/ZS6OvditucgKYn6fgYI630eXHktsAHiRGeSNF5LK12N6ATWjFAv79Gnun0d32X2XPkDrWye5X8wsfnM/JRE3szE2Qx3EsRQzgYacuvG66iMJu9YdIHGz7bendz32lWdjfvG2FVdYdHUBYRK1DzykuhnyVOmpoLVLNCDDgHoyIVrQL/IQsJXmM6IrPCU05IFSjRTSKKgFm408JiLmafLhyOXYN/jR4vaFba2jHxCudypRZ11+H0FPK83xT5FVfe2MeI/Nao/MS0NJZP0a3ppuA3W0hYeA5GsC2XHknDKsJi5nPaysTO08flu3P0DWx23oZL/Fo06URNJ6krfFMIGt2z2L02wDFUWBlfSseeyhm2wRbqUqiWkoAYMESa3T1nhFmOU8OJW52myjtmsjKeLG3M8oai9+8w2n7BPjrM98QIuwqvGjvn/s8xxI3KQ8+zzfeUp7WZFjrv/f7Ai/EMb9754o8VszGWTqRlWi7SMBrlwQhn7iYGMWll+s+ylbqaCZ4RdTmYz8v72M87D1vP+PJJrv8wScVLeBa/gcobo8xrdDzx92Xo72LOsvuN/ionYxrvqu96D9a7p8du4oz329DjK8zEIJ9bOsysjGk/i2moZuPL8Jjvbu47LT4u0/BLnxGZBhZGfvPnmOE364nc8lLkZ4mTpr4C1fiis82taI0uXaxg+wPYHT2T4zpN8cIETa/NXuxd2NfrqLFr3IkJmeeqrzcs3M+MyThjTGaxuiXQMHz3YbNq67RxZ7EYEIjoFC/5fzNbiBzDL9zj3er0EF5sDlhFg93i5iQpTFN3Fj8mvRrry/LNasE2VwLA1RS2ILmlPmSY6RYRzH/13sgPjNEjWObrF26K53nin7Y6qGXF5G/We/cSNvvbsKffL3n/Mu+WF/OjTJrRSpa2UDimzxFLxOiylXzJ/n+XvfefQGKt2Thh2hitgmJ2Ln5kOuE2Wqbs7kQ3v31xvsnSVbXGCePPtloj29AfsPiZvgRnH7MK0O8PHHLznhH6ff8Ze+7XxrthfCRkrsFne7Ygzmm1y00rT5jyWzVdpHiPEiRmS7ljxjvpzb+ghXyDwhkyI+sHf7kSjRXeDwuEiZx0e2pTVHrCm5MfKY4/4PVJaJm8MCh0l0qHGd8L5Q/lO7H7lVUW+NqhRe805unmJzDY202fM/bYeeZD+G5y+BwM0wZ8nrxv+CeZ13nlhZPnZ4mTpuYtqARBEARB+DgaPYwc+0sQJw8JVIIgCIKYB2TXtxim8B2Mkkc545AJ4nQhgUoQBEEQ84AagrbYhZ1vNuFG7rayBHG61Eag4ngRolpQnhDzDpWB+aL6+a3GzMux3tR6Wlvq4Htq4z0xM8jIyMjIyMjIyEigVoY6ZEbdoDwh5h0qA/MF5TdRFUigVghyDNWD8oSYd6gMzBeU30RVIIFaIcgxVA/KE2LeoTIwX1B+E1WBBGqFIMdQPShPiHmHysB8QflNVAUSqBWCHEP1qE6eyF1efFsUanA3o21I+m1olN2ykSACkF+aL04+v2P91gGMBgn020vGLn7sWtyi1NrmNwDf5vZC/Ja0xwru6PWpE3aiCBKoFYIqguoRlSfWntnKivbRL0uEQDX3OSeBmsvR/hA2k/vQblzK2cvc3DLQ3R5WgZVruv2v2KbUV1HG3KuaYLyI+WGi/Ja+MLhdqo8ovyW3lMVzLN8aEqivYDv53A7DKQpU3I61mQk7UUQdfE9tvCdVBNWjVJ5IR1vKOR83SiyTQA3D8qmz/C68y/fhvhAQqGKtxcXWOuziOot8z/olaHS2DGHJKkfcO3txGfq7mOPfwz7uY994HwaWSI25V3UhvzRfjJ/fUiyy688sdGBwUOLljvRbQugVi7yjvQRWOqfohz3Ehp1IIYFaIagiqB4kUOuKapHxC1Ss4JYXLkN/9J08wuD5a5zPt1y84FQ4r2DQvmC9A1H3qjDkl+aL8fObvfudNty//wtWrs6Va6k8ToF6+CX0W+dO1w/74GWeBGoZSKBWCKoIqsdkAhXHTD2EbgtFzBewN9yANm+183Xx4hilRHcVn1loQXdrBIfyV94l7R2jZXYdN6Gz9QzuZxw93ls9m53XaMP6cF86yRJhPNqHYdKVz8Lu7B5sjcwqIO85WXicHrH7LXZgsPcVJO2mvK4DiXVfPHcH1tXvLJ7t9R0ZNuxiT8ev7e5tQYc9P3+sLpInUL+DUf+ypxXIFp+isnSvl/fV18bdq8pgmhPzw7j5jeVhCd/nKLEZ47cYhyPY6rZE137jfdga3LEFKvqkTRyq8474AJTiVPgJYaKMhcaA2kN0uG/pD4zdqWL9o+P78PfuM3uXq2iBml8X8DivM38n45f5Ha/fuSPSlvvSr2HQexhZHzDY/Xd6mOZyp669AfROaTtZDN+sUxvvWYfMqBul8sQSqPaYqcbyLVjfQSfwPewlq+y42aImu8Z017AUNWeWoDt8re/LnYkjPPm99HUHsMscV/OS6eiZMxrchJbaElA7H3z+tyXCiGNg3067pVUl1OjBkDvhvOcYLYcKdT0+Gx1sMhT3VRWMMabsaJ+JztYNKVqV85WO3kybxgr0Bl/DHu9mV+EKkSNQgxWsEJVCbH4r88iNn3PfqHvlhfP0Ib80X4yX3+gf2rIsKP8VKPtRfosheyi0z2G+Yb39NlzSAlWWIe6/jGfJMpd+/Nm+OBWI0u8uqCE67H8csoM+nH/gxvtw0Usi/bW6r/UsRpRALagLdNop/ybmJpjx5x8KajgR98vMH0bVByrvlqHV/1IIXjkcKT/M06MOvqc23pMqgupRKk8sgSrwdUlljvHB+/ZknaP9z6DXYl/z6phH6Hi7jt3z8P+lG7YIcsJZHEblyE0xJYUitn7isYjnZPGLNBEv9Wx0mCuOiHSu86RNMcUCNRtuWVmYAtUjMEXa2QI1/17RgT4VyC/NF2PlN5b1JcM38TLgL/tRfksJMadMZ32VEnDG/QJlLnMtP2/R8nvsYMYvZJ+ZPcb/N8uyz/fxY/Z9MhTWBSK+6X3d8Ir/F60eJOYvVQsqxjnXT6NvbdrDMw62qQV1AmrjPakiqB4nIVDF/47Ddsk48IDAcc4T95YtjK5Z5+SFUT7LqSxMYp6TxS9QrTj8IP/23VelWSZtYiCBGgumNTE/lM9vfJcLPiI1cX4rVG6yvkrebwyBapVTE8ePZ5/pPyZQQwJE97wVhgiBKu5bUBcoDkcwwCFSLKzmZE9xD/bsVhceDcyu//S31IcaxtNepScOUXgIA2eo1UmD4Zp1auM965AZdaNUnowlUJVQKitQI8Sd6qIqEEHFYZTPCgrAuOdkiYjDPzBNPZWISSZtYhhHoJrhDQlU575R9yqTZicP+aX5onR+81Y/Vv7YdVlzJ0vF+C32v8eXIllfNa5ALS7/KizF/hH5Xo7rvMCEXQLD3SfZ8BcKVBWmorpAjkHlQ6N2YHfLjYcaBiXzQI/pj/TTutsfr5fjUHOHS00PDP+sUxvvWYfMqBul8mQsgeo/J4PrwCMdvbi3Gr/kpziMnkrAIeY5WfLjwNOR/70Ije6O1RJgkUmbGHIqKBXfzP1EeFX+iji7aeJWAnH3qjLkl+aLcvmN7/sNWPL5LukP7Xe/KgLVdy+Jc73vPPuYGnNq+D9f+AsFak6YNHLMqR6DmuPHUMiqSa1yTL+4f5yfxkmsiZygVjzpdDqQQK0QVBFUj5MQqOo6PoM02TWE2Gt4MfhC3CsjwgKOyT1P/Z+Z6ckc3fqn/JziMKpnmV/jksMvYTD8j6jnZAlUVjw9VLxUBeTOisVK4RELC6uUMmkTQ45jZ4j4O+KTh8tw7vy57hg2jNMlS1BH3avCkF+aL0rlN5YBd0yjRpVd8z2P9FsB35D1VeML1KDfcMpm9pnuMU9YpU8vK1DVdcG6IHNfNz3Z/9sPYdPctIBfI39XcQ766Vewvf7MEKPy/q6PPiFIoFYIqgiqx2QCVTkP0ymlMzxTEaNmhaJjMs1w7KobzXQUfJYrznhvQU/OLt3fvg0tnA2L1/NzvwvcW3W9RYZRPcu9jzGLP/85PqRjR/FpzRptWl/sYlKFe1/jq1459WMUqNxh485dajbs4S4kbc9C/XzymJoFfACjpONZqD/mXtUF03qqlNrhh6X5aBseYctOqfyeBjJfT6l1KQ4cE+luD5pPfH7LDSgcIWgihBwrm2aZiPJbzDPJcq93Z2O+Ybu3DJfwHGbCz4o8sDfckH6Fvx/qI1/5NNs/az+nVydxN9GI8Y+OEFdd8PxZW7D34q8wPPghfX7u+1JQFyiBKf1uuvwexn/E4voCXrLwLuod7VhY+WYialWUIj+Nadc0ltCSeUwtqGNTG1U3WWbIQnJKXzp1JSpPlNPQhd1v6KzQeZjOIXWW5rqAzBpt6KsB7vqrWpnRWsDFjlwfFB3+51twv4njoMwB7mp8lKoA1NezcqzpvXPDaK5JiM653XcG0YeeE0K1PPwC+o9ucOedbSkV2OugpufoClBZzPvvyy+f2DEqGnvtVRMzzpgmGzC0xKkk6l7VBNOnGFWRG2lqGr4Lj7b9Y9nKCFSzLJyoQGXx2/4Utq13q+oC1cyTgpY7A0zbQjJlyOkh8PgWKwxRfgs/RhLtT1Cofo7roOp36e/yA9e9vxRlWtx+l3039bvj8Vlqybsy/lGvv6p8ABO6GDbe4/SPnOf7yKkLjLhpP/IaywQ+F8eK/iDe09x1pfP8NG4R+xns6XRX9415c44fDN+sM/sxkEyUGXqgeqhFiBiHOhSQ6uLpGiMqR7kyoCp1s8vVaFHS6zNOwFgt5hOCrX4rN2fyPfV1UedBPo+oCiRQK8T4mYFfyjdh5f4deBe/Givd5TRbkLOeJiRQZ4GJBSrH1xU7Jqr17sQEqujmPK1xeJNCApWYVUigVoixMwMdNh+oHtrdxsDqavR3p9rn5HRbcrAbJrzVpN01iy0oxvaYeh03Ft7dv6XPxC4fPjbJ4NjDHQc56ymix6Klu0YR1aNcGQgJVHXcFUrY3ejZgpKV5eB2ixmBKj90ZLn3C7E8P+V0eVr+RYpTflyaFKpx2w8zs7poQ+SFQYRdjbvd3Ut9qh6faVK0PWgBeF+CqAJ1eBdrU5rGywzmvIa3YVk6n/yvZdmKoSa2yAkpwiHKsTT82IqeQSh2sWAiIuOEJeaYMHeryYO/ia3q1EQbNQyB38usVBqw3P1EDoSXosV63hTCHQnen5gCeeNqiUpRrgyEBKoq7+bx0BhJvEfOdosZgcrE3U4furfNvdEdcvzUzu7vIX+bShknswU1OBZWjkvVQxmUwM2bLIhRxAlBgTA4Ye+uf87jae+4JuH+M2970GLK5TdBTI86vIu1KU3jZQY6/pXU6Svn7euO4o7OcVT8WNrthgJ3SU/cQVQlktM1F+py48fNbdvcLl1fZeY5Nq1wR0DOmph3ypWBbPlN11M8l4pOg+xHNfqJnO0WLX+DAvAG3BjspeeGCPgp/nyP+EwnMHoEKuK5n4hLQJz7fLKkMAy+sGeOxW4Pmg/5PKIqkECtEONkBjqfaGEmHVrqeBmW+FOVi/xatyzHwQUcf4rRRYX3KitQpxXuCPAeBDHPlCsDvrKYP9wmK6DUPbCb27PdovI3jXehW2L5pGI/hUsy+baplOEpFKiB81jo4j+WA2Hwhd09Jv+3/CSDBCoxq9ThXaxNaSqfGWrigVkZpJadLPU97GO3ll63Uf6v19sUX/qugyskx/GrMai4L3Ay/AK2xmlBnVa4I8B0JIh5plwZcMuvmmAUHmfsFVB6DCr6MmepG+VvGqvQRiEXO4Y56KeYP+HjP0PbVMYK1HBLabFILAiDL+zusUzLr4AEKjGr1OFdrE1pKp0Z6JCWsqJQO0pL5ElwPFfvpnDs6PwbbVgfqglJ0hGrsZ6xhBw/H3NqblPpOvBYgcqYRrgjIGdNzDvlyoCn/Kpx5YHymSegvNstmv7mQIxrj1q+yuun1HhP9bHLyAg9GadCgRrwXQwRx1ALakQYfGF3j5FAJWpGHd7F2pSm8hXBSrDLSDmlVBwi2OLayu1mEtcxJ2fOtkcOh7CejPwOLuD4s91a4wrUKYU7AnLWxLwzsUBF5ARJn5DMCqiC7RYtf8PEHV+43PV1Hrx+ytPqObZA9cUFkeEPfkBHhMEX9swxz30Y/jCFIZ9HVAUSqBUiPjOkU150HKaJcl5nmtBREwik08PnuJZuJydbO9xz8rrR1H0tx586RlFxqC4sFiZ0oHtfwGC4KxxqRozisIVsa0ImTMwmCncEeA/CQ5ndf44DXEJs8z57f97JtE5NE72UkCtO5ohyZSAgUJXPQtHFh/uo3g/VemgKQhRa4e0W9da3WvCpIT/5M+X9fkqFV/obY6k6c5tK8bGNcfoWDvkxdgO1Kon1bij/lfrdo31c0mop9cMZIsLwcisbdvV8Q/jGbQ+aD/k8oirU4V2sTWmKywzlzITD8U0CUq2J6TnMuGPzrOmnzbiP4SDxt0yrpEHmWZazNp7Hu+T34DV39E1o//530OUCWl2LLa1fScFqHsNW0+MPdyx4H8LDiQpU8513hc8U0R957LkkUAtQPSaqXEqzxKASkvK3hV/Co0e/tK/h54e3W/T7G2fLS+uZglw/lbtNpfQf6hy1RnPmo9l4LzN+yBTkAXLC8PvkVjbsSrCax3h8mODP3R40NxQcvK76YIPHE7GubbBsYlo8Syec+daMRcx1Y31rcHPMtW3PGR9PAbyNKuk74q2jF96G//LO/2EfMwzfo0fuero5jTe2xUzQqx4Y9lmnNgpi+pnBhF7yKbzwOCn8yr/R3S78uj4dTi/cdSgg9SDUMjdt/N2m8wSVgfmi+vmNH0M3Ybm9Kj4CvGVT9TI6E2sb78PAFKn8w6Chlz/zt3aLBpJFNTxFrsur15rNQQjR0PCKgE/zDR3RG944S7UxgdpZNoW3x1+xD6ad3jIsRQ7xqBIkUCvEdDMD18j7RfglZQV1MPwP+U+VON1wU+VcFVQLHQnUk4bKwHwxO/mdUzblhgW2MBTnp8McfOvGOuOd8QgfNuH4Hd5yWdwqeVwCleMZUnI0egg9KwyBNDHXEZ4hSKBWiOlmhhwb5dl2j4+z2xwWfg2eDqcb7uI8cbs20dl86xxTjkw6DzymHYjdDYVj19r9gdEVh+siJnIryK/gQJ+ruj1/yO/GsrobVfeh/L3MVrMW2L3mbk+p1m/ESuEL2NPbNhZ1h4muOlwjdxHH23m6dQV+gZq7la7EnAlubyEpyUsjw+Fv7X6ePsvs/lWYXYX8Pv3sGp4uTncwpn13S73n+G4Etuc8YHmXqDG5fze6H9n7w3dTK9klmQOGi5gfYvOb+1/0HzgXYu8rSPLKRpEfUu/y7tdil8CouQNhgSqEoSsgHfEphWBmXK4lPqWIzDzDFbt+jlWg6iFHzvkW4TSZRerge2rjPaeeGegk+EQTfMnRUQTGtVSNUwx3bJ74tx30OBr8su/clZMamADBCSJ6fVfZLcVEhVhSxxS/6NTvw+YQhaMay8eEx6270N+U27u6YeBdUaHtXw2xXLjVrIkdJvEsJ5zLt2CdC1zZQpHjUM2xWOlYPTcd+JnyGca9ZCuJfytdfoY8lnbZqQpDX5ObRniCSicl/Bh6PKJRicoxubr7zXdOBpk+epKLmmAj42iOL7O25/yv0P4vaqwaftB8Kip7Hhes3Ftw6/46bHKRUJwHRcSWAaIeROW3FkvsHcSPqkQ2FPje+zJ+qDeAl/xD7O10kmyQkBgLDQdSPkSIz6B4lOWOi8+QWIwUgscqUJU/yITFJC5cs0IdfE9tvCdVBNUjPk+kY7Cch8dZZLZsXHScl+1E+RGfkzOdqDzkOja8Ln+XMZ+DDDl3G1+YYo9l8MUlI6x8AhXjm7eVrhB8dhqJBeAX5bHiNPI7fPtjQKZZoEIJt7KI69Lfs3kfrKy8+eS5nhGVBzmQX5ovSvu83LIh3r/yfigG//P1/TLHVVkQzzX/tpBljpdL82/5syD8DBPxDBTfeebEO1PmsZcpEb1kujEjRChNZhNMn1mnNt6zDplRN+LzxCOg1BevdoJ4zn1Yl78HHaQjbMR5jsAoFKjK6bvOEM0RVpaDjKssfGGKPZYhIOTsaz3pqxFd4ZmtdHl6uB8AJjFpFHD4Zlr/EKrESlQWergFPtt4JzKVlcKXTyRQicmJz++IsjG2H4phVgRqqOwF4q3Sz0qrJrTXdyKG6ZBArRq18Z51yIy6USpPeDevEkTYAtiBzta24eCY8+g9lELDLyY4jijxOrlCgSocVdaxmvgcZFxl4QtT7LEMEwjU3K10+X3znh2TRgGHb6b1P/zhj0pLNTaPd5PuwO6W804470KK794kUInJic/viLIxth+KIfB8db/Mcbt8iHLh8b+mP5JxyYY/9Gyb/LIXiLdb5uWwiezW5T7iwjUrkECtEFQRVI9yeSIdDjoWbFVbvg3Dw29TZ/lyYM2kDDovxyl6zysUqDIswd1rEJ+DDDhNB1+YYo9lyBWoqgLxCFT5QZDuIOQ4Z9fRZ4hJo4DDN/Mo+Bx5/2BloSYAqud7BGbRva18IoFKTM5xCVRRnmPKWJzPyRIWY+Kdd+8ny4flHzw9LNwfqTIkw5Ypf+LZrs9yyS97gXh7yrwaNlG4W1pOmswiJFArBFUE1aNsnijHeD+5AyvSKYlj5+Cd1jJ0zK/1kPjgDjLdScvr5AoFqrqOnRPc/tXnIOMqC1+YYo9l8ApUpzJR/+tw+cSY65zl/+z57ooAajeg4jTyO3xRYag8CqUZXnspXKlk4u2JU+gd8T7TlybsaEwe5EB+ab6YWKBaAk+9f2X9UAyB5yNe8emWR/lcq2zJMmQIahF+J2yOjw6RX/YC8faWeTmhFifGmuugZshJkxmEBGqFGDszeDfhTeia4qdysILTvQnrfJb27FA6T5RzsWaxqmOu01BOhwkotehzZhFo4xxD6AiBxJy+2e0jBY9urSjc/lU6M8tBqpnkec5Xhcknrkxn7A97BhVuYwKAWDDb3KlKhSvdzlI5f3FvnEjgbqX7Hzqd7DQwwlOYRqoScWfxp4t7c9QKAnohcLnSgrswuIl6L2R+pUtmYeU+gheDL+BApU1GoPrySU0sM7f8TPMlNw9ywPQg5of4/Fb+wxBNciUJyy+N5YdiyBNj0vdon3IAo6TjWajfXH2DXcOXuXMX6peTLdVC/Ye7kLRPdqF+gdpREZfKS4yl8AxUWpNArQy18Z5jZQavLC+nlWeV4QX7csEXYLUonyfC6ditgb5jCkNYcadtLNmiHZjh1Jv3YYePUzSP9WF3V7RS6GPKQakxjvK4bsVQTlBfg6IotNWsiRI86hxmzduQ3LPDiXuIv3TO88efIUXYwrv34REuk4TnW+uBqgpM3Us5fGMLXHcrXV0esNLJW2eWEUojDa7x2k/zyLMmL2KvyZpTiWhY2ORyWnoSxGtMCyYm2wnsDu8F8tTNO0yPbTH+1jr2gqWPmy+BPMgBrytD4bqzGs/7bVSsejkiFNdWC7gJivI2rORtuavX2UzTTC9pdvA5JNvsHc+kKVpIWNQbjHscSiD+AvqPbsjyE8jvUn6ouKFFtcqm1/nyyvSt+A6Z6xunWOWW+xFPI4oV/ogJS+rD0gpjKkSz4Wfm3erUiZdaSk7+npZnT1lCy4jc2QLjMOvMfgwkpTODfy1ddr72Kg4Pc+OE9nCfnDoUkMqjBOoY4omYPqXKAG+RWsqsGeud4KFanbEilabfAS5cZMsW/9sca6xAgc8EyI1QS5ZqEVtIBan8hYtW3ADBFQD0LpbI77wWTIKYnFK+p6LURkGUywzRnafWc5wleLfrotEFXmHqUEAqD4mCShNfBmQrjtNqI4ZZmMMOkPyWT9HCpFqc5H1dIYQCt4UTEf3iyDsMxgKHYdyEZRKoFiRQiapAArVClMoM3vpgLlKunHqoNUK1VCin73Qtu10bTpeM3eVqbr/5hdjd5oyqgNh9d+6Ibku+5d3XxtJKCnRsl2ai+wzjTkyXYiFBnCbRZUD6mYy48x3XrafYJfzQ2RJWDSNxBKo5Vg97YlbaOR+5aliIcY0Pdp/N9c/ScJFALZHfarzjbDQ2ELNHHerf2iiI+MyQDtzz5Soml3gqCawQmr+QjkS0HLTUuC4mRnF3nbRCkJMt9ExGNSEDfzf3mV+AxvJtGLz8m5jY092BAyaSl9Rgcv4cJl4z42DC4a8aJFCniW8862yPmaoj0WUgKO7cljY1mcvIdxSqxtj0/BbUiHGnMiylW/dIoMblt0pfnX8FHwIEMQZR72LFqY2CiM8Mf1eaQIk/86sWj92AJdViiS0aSzdsx205ZnH/1EkrIeEuHeIOTBfnLVotYaxyyrSgquur79TqUEAIYhLiy0Coy1ce93yo4g5gCR8LKkSqHgYgx51y/8JbW9UYVHbN8Da05HjUdIKLOZHK+PAp+8FDApV8HlEZSKBWiNIVQcj5SueeTirA81e0GHSHAljm3jOwBaNfoKb3xkkJjzwznRXivLgZm6cJpglBzDPxZQDFo7NsGvaiyKFEeaJP9fyk/gfFq1p9IRWfeN6N9obooZFdzPy+6m/+cUwCdRLI5xFVoQ7vYm1KU3RmyDFdYecru9BkSwaKwSXdqimdd1HXlxqDGtiCMSRQeYWkxqBiBcHHoWZdffj6akHOmph3ypUBs/yjsLwvW0iLPkYj/JIz7tT+yFWiVPTKiN9IoI4D+TyiKtThXaxNaYrPjIIWVER2i4m1EFesykE477yF2OWYUz0GVTn/GIEqQYGbyJZXzyB6u3KpLuSsiXlnsjIgFzmPmADHfULQp+Gatzfghl5Sz/VJzv/qI77sMCISqOTziMpAArVCxGdG3hhUhZpYcAkaDWe8qXLe1sx8hFUm65/C6B+uk44VqOy87YewaYpR7vCzQlRcT2NQCaLqjF8GArv3eEEfczMw8cked6qwP3KVj1I+RQ03YH4sTxzjh/SnamMMBglU8nlEZSCBWiHiM0M646Jueu5s/d3w2Vm0aHKSghKwwS0YX8hdgjwClR1fbN2BHV4hsUoCd8rJrHkaGf4KUIcCQhCTUL4M4LjTT6HPfMaC9gUGKAo3E9jUy9rhsIC7wQX3cRmylRWPyOTjTi+IsfbWGFT5O96XL4HHBGdmTDyGMYFe96FccURCApV8HlEZ6vAu1qY0lcoMzzqoGbjQfCfQSokO2tliU7emSmGJ3fOZLRg3IOn+Z3GNNKuldftT2N77ChK9dZxvDCoOUbjk2RmmemAcaoHu8vTlG0GEiS8DcugRvlt5kyT1snbyPcw7F3eiWg6vd2puU+kVw+jLrJUCAs/0lI/MNpNzAsadIKpAHd7F2pSmcpkhWkFzd5I6GEDH1/Jw2mArBe0kdYKk3Z2i4kXLDrsgCB/1KANELJTfRFWow7tYm9JUOjN4t1ZgL/6jPRh03qmeCOHhukx78Z8kzuxngigDCZb5gvKbqAokUCvEWJmBXWCty9BOduFQ7/gkWskqt3Xk4S4k7cvWjjFVp1yeHMBoq2cssdWGvupGzHQhqskccjIbP2ZMQjO6LvUwC56XRpdlsw+7e3LnsGBeG62nOIzj0bZczDwHN6x6rLAZ1rT7MxxW/mPOlrn5cTna/wx6fB1Mds/kK9gb3If1ik+qqyOYb8T8EJXfpo9Q/sHyG+YEWBxjnLf9tTPczNx2G9fhTu6z396B/i67rsP8jFoVRg8Vkevk7g2gtz5/QzLqTB18T22859iZwUXATegO9uTkp3Rh6+rwCgbdm/Z+/zNAfJ7I5XT0Nq+4LM4yywtzdxxsPUYh565egMKvrZf94ouWt27IsbvKuUtBKCdxCEe+Ar3B10y4vQ8NvSSYg5w8ws9XtrDMnH3B6FMV1sxENoznOzpOuWGVw1D8W+ay+OfF5eAr6C+t6HCKhdxD46mJaYL5Q8wP0fmtfIvpI7S/SX0crrYQ3v4a/w9tu/1Sj2k+c6YBy70BvOQfsW8zX/m/mM9cThs7uL9amssxw3WmDr6nNt6TKoLqEZsn/mWz5KQRw4HbS+Mo2Hm6RQHFqr1ubeY+qqUid5kxlwMYDRI+s5o7fM/atBm4gDQENoLHltRzi8L6LW9xzVuuLBiXzDhlvJZaUE8D8kvzRXx+Z/1b2suifKFc2cXq4TH8HZb/iG23sx/1+Oym45u2qQW1ZtTB99TGe1JFUD3i8kQ6UctRIx5BJp26OYP+aO8ZrG87go09N2vSSY8lUBWyBSNqhrKMl7Vhww1YUtfFhFUR2DI3GBd1PHZYAjE1MD+J+SE+v2MEKivK/KPcv1qD+s32HdK4TwgJVHX8HLS6D2Hg2a2QmH3wPZh1auM965AZdSMuT3yOWiAcsCkGlWhVDpc52vX76XW89cBtYXWYSKAiWZEcAtegXFbhwecu/SJt1YwKqxyDikLTs2VuXlzSMahYYeE4VBxnTZw05Jfmi/j8jhOo6dAfKTz10oPSF3r8ZkpIoDL0cAC8bxWHtRGTUgffUxvvSRVB9YjLk7AT9Xbp621omWhlAm29t50KRS7YFvPXiJ1YoGJ434kcryXHjbJn7e72YckUtYVhlddaLbDxAlXAKrdhAl0uVJ3hBsSJQH5pvojP71iBKsGPVWf7a+Ef87bdzrmf5Gh/CElXCNXKTQwmJoIEaoWgiqB6xOZJtqUUkYIsM4FJOt1GFwaDDehbzlk5ZOy6ema0COBs/EeQoJOeWKCyiqXTKR6DKhFxY0K0seS0lhaEdedTYyyZOB4tUA8+g/VNU4zGt/oSxwv5pfnieAUqK/N521+r8m+t7oGwj1vcdjvYxf8KttefGWI0pjWWmDVIoFYIqgiqR3yeqBnqTb0urZh5vuRdp1aIvjNekSm61WV3mGG6dUBOIogRqNi6sJk8gaHaYYd3i3Xghm/t3CCyIiob1h9k5SMFenbL3C/gIBQXPL7Ygt6OWm4Gl1NrUAvqKYD5ScwP8fmtPjiVz8PeDrHFrfADWM7/zs8Jb39dsO228j0egYqTpFq9z+SSdmLVFHsyFjHrxL+L1aU23rMOmVE3SuWJGm8pnSxOCkhCy2rx5VguBLvZ7bVF0xZKLWyVFbQY2OM4x51QgK0Y4SEBobCyX3K2zE1gd3gvHJeDzyHZ/hpGSUemJ41BPS0wb4j5oVR+87WtRdlfaPVga/R37isa7fuQ8AlR2IJatP01ClvPttuqdRWPcTN6XrAFNfkM9kaJvI7GoNYRzPdZpzbesw6ZUTcoT5BXpYYEEPWCysB8QflNVAUSqBWCHEP1oDwRy1I1aezn3EJlYL6g/CaqAgnUCkGOoXrMZ57gJCe5PSpazKL+RG0hvzRfUH4TVaEO72JtShM5huoxr3miJz9lxosR8wb5pfmC8puoCiRQKwQ5hupBeULMO1QG5gvKb6IqkECtEJgZZGRkZGRkZGRkJFArA2bGX/7yF7IKGeUJ2bwblYH5MspvsqoYCdQKQY6BjIyMjIyMjIwEaqUggUpGRkZGRkZGRgK1UpBAJSMjIyMjIyMjgVopKi1Qnydw78P34Mr5n0D7wZb/HLLp23Hkw/PfwdpbF+FK74/+38nIyMjIyE7ZSKBWiPEE6hN40PsVXGv+iF/P7WwTrn3wMTx4+txz/ji2BQ/aDXn/xpQF6nN48vEt+PjJcYW9TnZM+fCkB1fOnoWL7Q147vvdsj/BvWtvwpmLbXjw3Pc7GRkZGRnZ8RvWdbPO/ArUp7+FNhOmZ5vXYO1eosXG8+QuXL9ykQnVt6C98SR73VimxNGUBSq27v30Z9AjgRqwcfNBXnf+n6GXPIbelZ+y6/8AG+234OzZq4H0fg5P763CeRTEJFDJyMjIyE7QSKBWiFICVYrTM+dX4Z6vpfQ5EyFXUaS+DWuP/5z9vbQ9hye9q3B2qgL1SYFgIpskH54n9+DDtTX4oP0erF69Cj9/rw3X2f8fGh83lj29C9eaTWieP0sClYyMjIzsRI0EaoWIF6h/hsdrbzORkt9N+/xBGy6ye559aw0eo7h4+gB6a3L84sYntoDFsY3Xr4jWMjQcJvDRA3iq7xcvjHQLLr/XRbhy/S4kWtz8GZK7/wrNs+y381dh7QELx+qvmPiR4lQ9n4eBCdXHG+Ew4/1YnD661pTXnYXzV9rQe+C0Gltx+xE0r3U9wx9YuO79G3sOE2N43vkrcF0LNzWM4scsvfvwWJ/H7rV6x4hbnj2Hpw+6xlAMli7tnhGO2Gc4+fB8A9oXZZjRtLg3hwPI94Tn/wdwvd2G9woF6p/g3urPYe33fXF/EqhkZGRkZCdoWH/NOvMnULUoKRCLfKwhChQ87xH0rvyYP+PMmfPw1moPfv/4I7h6/j/BtXt/EIJXt8bKcYfW/eME6vOE3bPZYsITRaISo6mQRtH8ZvM6bPDnsN97/wzntfiRokqLrD/mhPlPooXv/I+h2f6tENKqVdlqNZZxUXFTLcv8nky8X+nBEx6On0HzypoQjEzQ3l1F0YtxfSbjLYTe+bd+DtfvoqBTHwkFecBNdpXrIRfs/43rXKSLjweVtjHP8OSDbi13W54x7j+Bt9Z+x+4l0vZs81/hrtHF/2DtKguXex0+9wr8FK9T7xoJVDIyMjKyEzSso2ed+ROolvDMEUdayP5YztgOjV+U4oWLNfxfiSB1nXks75l4n586s8OlyOQiaMDv8YZq0VW/8xZUdb0pUI1jgTBnhJNMGx0X34QgfsyIG6bTmy1bpDn3Ea3R9n18x7zG8+EN57xsGsc9I5APPLw/kmLUOPamR1j60sSw548/hKutj0SrLQlUMjIyMrJTMBKoFeL0BKph2A38wTXRBV9WoOrn4bWuieuE4GLCr3kNPuiZQwjQSghU+axUVCszBTG7h+88R6CpMHnDLYVZjHjM3kf89v/x42ZamuEoK4JD+SDTSbeC43kteNO4lza+zNRPRCu077er76bjmkmgkpGRkZGdgmE9OuvMn0DVQjBHLKKp87TgyxGoapwmjj1duwsbH9mte1EClQsujxCzzBiDiiKOj0NVY0ZLCFRH3OnjmfPlMALdvS7/P/OmFGgyXtYzsza+QP0f8ClPN0+6OOJvMoHKzn28Bm+p9Md7v/lPJSfIYdf+z2HVFK4kUMnIyMjITsFIoFaIaIHKhUSJSVJaxIUEqjNOU4ugkgKVi5k34Py1u07LqMdQEK/Jllo9ZrSEQA0KJ889cIzm6s/gipqgZE2AUumkBKt5r9TixKPfgufJOBxPCyqazEeWJhsbbXgzI94LTLfMhy37QUBGRkZGRnb8hnXOrDOHApUZnyCEraOhZaSkWLF+D4i9TGvkmAJV39+dKY+ThD6ANZxw9PGv4EMzvFarawmBGjyOXfznDJGM6dDMtl6apsRuZuUCdu31WyVaNwMWEtM87qkwnlygqvPZR8L5N/PjHGvBDwEyMjIyMrLpGQnUClFKoDJ7ntyBVb4WqtMiGFyoX82Kd8SNEiGyBTVdJgqF4wP4Ta/PhKsUvEx8WhNxHBPdzJ6WN2O2+ht8JjmKVDmb/Q0lok3x9Qye/ua/w70nf/CHGU2JdL74PF4vu+/1/+ycnFZBMaNdXCdapN1zVFxVuGyhKBaxPxvRYmyce1VNPsKZ92+m/0c/oygfZB4fl6AkgUpGRkZGdgqG9fCsM7cClRt2lfO92ZmIUMLKt9WpEhrqHKd1VC17pNct/RMKOyaM+NJLSiSqa/NbDe11UM3WVCbCcBvTx+uwpn63xqAy00tFNWH1//kI/lswzKFnrcE9JU65edZX1WbGg4lbcx1U3ZqqWmrT685e+Qh+z8Wkeayo69tz/7V7UpzGPuP/hg8K8wHv9ZPc/CllJFDJyMjIyE7BsJ6bdeZboJIVGBOoa7fgN6ZYl4ZrtraufVyzMZV/hN5VJvq9wz7IyMjIyMhmw0igVggSqMdt2HX/T/6lltCe/hZ69/5n9vjMmhjicJEmMpGRkZGRzbiRQK0QJFCP2+R4zfNXoO2sucr3pf9QdbHPsqlxqrLbPzhpjoyMjIyMbHaMBGqFIIE6BfOM0fVvEjC7piemueN5ycjIyMjIZtRIoFYIEqhkZGRkZGRkZCRQKwUJ1OoZ5QnZvBuVgfkyym+yqhgJ1AqBmUFGRkZGRkZGRkYCtTLUITPqBuUJMe9QGZgvKL+JqkACtUKQY6gelCfEvENlYL6g/CaqAgnUCkGOoXpQnhDzDpWB+YLym6gKJFArBDmG6kF5Qsw7VAbmC8pvoiqQQK0Q5BiqB+UJMe/MUhk42t+B9c5tGBwcySN14RUMujdhfbgP047Zief30T4M129Cd/BKHqgqJ5cHhIAEaoUYJzOORn1osuvwWmEXoO0W9MMRbHVbsIC/L7Sgt1OugBU/43vYHybQbZ0Tv7NndLdGcCh/nWUwPnF8B6P+ZSONTLsM/dF38jyCmC3wHS4H+oMnkPTb0FjoRItFLi7bTVlmFqDR7sNgdCB/LeIIDnfXodXsQGJeM6Hv4+Jp8z60Gws8TM3+buH1k8VD8RqG3SU40+zDSD3wcBeS9mVo9b+cqm8tnd88jR5Bn8V5oT2AUjE9/BL6rcvQTnaL48SFLHundLpuwHD/e/ljDDHvJXuPRs90XbbQugM75jNOKA8IQXnfUz1mPwaS8pkhnRgvsNLcgscdQEMXqKP9Leg0lqAz2It01EXPYAV62INGQ1UMsqJYOAfLyTeRz6guGN8ojnah38RKzEgnaQvLCezNekIQcwu+w/EcwcHgJiy3V4WQiBWoh0Podz/RguNo/zPooUhYWIVkr1iEHO0lsNx8HwaWmJjE96FQSbgwXWh14dEg8oN7wngIpE/F9DMFKnL0DSTLjan61nL5/QoGnVVovysEeSmByuNyOTI/WD3Uv6M/PlS6xvvWmPdS1l2Ly9DfxecwQTt4n9Vtznt1AnlACMq9i9Vk9mMgKZsZ6JRXVvIK6Pewl6zCguXksKB2YCGy4ih8Bhdmi07LgnxuKadcTWLz5Gi0Cb1MKwCmQ4c54Kp3XRFEmPEqCSZc2hciBep3MNp8Zgsxhui5iWi15IKhmenVGd/3pR/Z5VrKJoyH4nAHuq0WtLDV1hWoDC7GF6fnW8fK74MBtBfKCFSRP4uR5x/t/RU2X7yW/yHl6rGUnPeSv0cXnHwS57vxmnYeEAISqBWiXGakLZvBL3zZqpdxGtyZeIYCZCh+hnC+2XuFjs8acXnCKrT9v/vTf+lGSQdKENVivEqijEANEOWnZGuj+5xJfB8KxMYiNLo7JcRpDtH+FmE+t3cLkpdfiB4Zj0AVaXspXvCWZKz8LitQeRpfmqB+wLrp7THyKPxe+uuskBCebh4QgvF8T7WY/RhIymQG/4JjDgGvUbbQWofdw7S4BL/cI51J8TNk4fUJ0bIOq6JgnMcF039pxuNPEOOVgckFKvdfhdeL57h+ZnzfJ8eS4zj6R5+k4+r1EKbyxMUDwVbFNqxg17EaMuQVqOO2HsYxVn6X8veThf9ofwhJdxmanS3YL3156L1Ucwjc+QKhOm66eUAIJql/q8Lsx0AyVmYcjmCQqEH8zEEYY3KEk/aIx1DrQoicZwQdEz9eolurooxfQNDhrUzQQkAQ1WC8MjCpQMXys1w8zo/7MneI0QS+T/3e6kIiZ2uPN45UERkPxtHeJnRuSNGVK1DZzzx+05l8OVZ+lxKoUgwG4hZGiUjZYDLWR0OBQPW8r6F3aZp5QAjGr3+rw+zHQDJRZhztwaCDA9XTAhPlpJUjVIUeLeQ4PM9IhwE008Hueral59kzxth5gulK3ftEDRivDEwmUAvHvisCH8JjC9Tc+6njjlDi5hcq0fHA8Y+duzBUvVNRAnU6/nWs/C4lUOW7kYlbbLoewGjQFw0m5kdDVF123AJ19uu4KoN5OOvMfgwkE2cGdxJpgQkWINOZlBGoiPMMDhOkOz25lAsTqu3+Q77kyLiVU5UYN08w7al7n6gD45WBCQTq4Zew3n1oDVcKIXxcCYFaIKRC97MFY6SQio4Hdu3fgt7QmAQUJVA94TwGxsrvMgI1GLd44Y9k0mAqAjU8jG2aeUAIMA9nndmPgWTizOAF9J20QPP/s91fXpEZi/sMH3wA/IX5WmbKAp3djfw0IogZYbwyMKZA5S2JXXtZnzy4LwsJyjF8X+79SgyLKhMPKe64oAqY+9ygAD8G8HmlkXGIS59QC2pJQnmcS/i9FGnqCuLwWNNp5gEhGOtdrBizHwPJxJnBnETH6k6SX4WWI5AFrtFLu5PKkHmGA1/IeAkaYw1grx5jO+ulCZ0vQVSE8fzSGAIVhxD17jqiDteiXIck9LEXFCnj+j45ZMk9hwuwSDEyTjxcpCAOiTi/mDoepi9QfXkzBvyZZdMg5730vkt4/iXvagHTzANCQAK1QsRnhtwRY3OoRSAfyN/2fLHL1kyxnt+RXHw6ZrHqEs9A9I4r7Fm9z2ohTpHyBQQrwRuwVOqrniCqy/ELVLlGqTl+kH/Yqt2XHMsVMuI5XmEU4/v42pfOgu9qmSn1kS2HMC3GLAofFQ9P/F1yBWq4Ve84wLCWppRALRt+db6xQ+HYOzrlvZdqyTK1UP8BjJJOdqF+znTzgBCM9S5WjNmPgSQ+M5h43LkDLdUtxJdE2YZRoFXA2nqv0Y7cSzjyGdIxnTlzDlrdh2Ns6VdtyhcQdIAr9FVN1IayZUC0LEm/wc3tMncEmhSJ6fl517oE1kGVFPo+n0Bl2NuVNqG9vlP80R0dj0kFarhV7zjA8MYjW0OtuEa0KpZaB5XlMd84IU3LRvs+bEbVYynF7yWCDTMbcsWavO1Up5sHhADzadaZ/RhI6pAZdYPyhJh3Kl8GuDB0d5KqMdgoULWdpEojRHrsTlKVY8p5QAhIoFYIEkPVg/KEmHdmoQzwTUXcvfjrCF/q73KF9uKfAP5hEbsXf4U4gTwgBCRQKwSJoepBeULMO7NRBmQ3cHP8HZ8qz9jjLstxovl9+CX0W5ehnezORlf5CeUBISCBWiFIDFUPyhNi3pmlMsDHjnZu13DiyisYdG9Gzh+YjBPPb76xy03oVn6IxsnlASEggVohSAxVD8oTYt6hMjBfUH4TVYEEaoXAzCAjIyMjIyMjIyOBWhkwM/7yl7+QVcgoT8jm3agMzJdRfpNVxUigVghyDGRkZGRkZGRkJFArBQlUMjIyMjIyMjISqJWCBCoZGRkZGRkZGQnUSkEClYyMjIyMjIyMBGqlqLRAfZ7AvQ/fgyvnfwLtB1v+c07d/gzJvVvQvnIRzl7pwRPvOdKe3oVr538Mb639Dp77fj82ew5PH3wMa+0rcP5iGx48951DRkZGRkZGZhoJ1AoxnkB9Ag96v4JrzR/x67mdbcK1Dz6GB0+fe84fx7bgQbsh79+orEB9/qANF2UaVEagPunBlbMyX6YtUJ/8O6x9/Ef/b2Snb5Q/ZGRkZNGG9easM78C9elvoc2E6dnmNVi7l2ih9Ty5C9evXGRC9S1obzzJXjeWKZFaXYHKTQrCQoF6kvZ8A9oXz05ZoP4ZHq9dhas9EkDVNMofMjIysjJGArVClBKoUpyeOb8K93wtpc8fQ+8qitS3Ye3xn7O/l7bn8KR3Fc6SQC1vUxeoz+HpxnVonv0xXCEBVEGj/CEjIyMrayRQK0S8QMXWmLeZWDwLF9sbwS5q1eV99q01eIzC6OkD6K3JcaQbn9gCFseYXr8C59n5GA4+TOCjB/BU3y9eoD5P7sHatSY7F+/1I2he6zrDDZ7Ag49WWYUtn3X+CrR75rNw2MIatK+8yeK3Dk8edOUQhrNw/soau9cAnupjLH7Nf4W7iRThWqD+Gjbu/RuLKxOG+joVBjVWFe+v0k8NlfgxO9aHx/paFv7VO5CYwtJKK7z3v8E99Xx1Lx2/i3D1oy68FyVQMVzquSJdrhst4/jcu6uYrjI+j3uwep2lDxc/Mi25oRD6gzX2dePxR3CV3Ve/C3xsbJqGGM4r7V52WIgVV19euuc46YHv3AfXWPjYe7Px/6bnsfdr9a4RN69hevwaPmDv0htXPoLHD9Y8+WmP8c3GkxkLw0f6fcRr29B7YPcs6F4HGTb73ZdWlO+l8kcJ1aKygGa/F2ebq/CRE340Kw6Yn9fvyvdWpBGm41meRul5VtkhIyMjq5Chj5p15k+gqha5IrGoxz/ieY+gd+XH/BlnzpyHt1Z78Htemf8nuHbvD0Lw6tbYP8G9a286948UqHxs55twtfeYiw8hklmFfe2urHTFvc82r8MGf9YT2Gi/xe77IzkeVD0Hw4kV/XvwIRdprJLu/TMTB0wk/fxdaH+4we/3/PEavHXWEOoqzuevwhqvxFXrlRLq9v3Fdc4z3/o5XOfiSX0IGHHmLdM/hStr8vnJHVhFkafFp7zm/D9Dj1f8LH5M1Fw8VyRQMX4/g6YSXlrsqGfjEIu3oNn+rUhHHo5UYIt0NoSPzntMi5/Cau8TeIzpx/OYCfx7q3BeDwFx00iFSb4H6r1QrfI8nfAjoAdPctPjj/Y7d+2GEEPPfwdrb5lp5jdrTLEexuKE9U958WRhlmONdbqpngezZ4Gf84Z+R58nQuSKcMs0Lcz3kvnDrags4DksvphXZ95k5fRP7H9VDmScz16F3pPnIszNlnzn2Tl3/5WlkXy/nXfh2vV/58I1U3bIyMjIKmTos2ad+ROolvDMEYtayKqKMTSOVBxPu8WVYDMr1BiBKitcs3tdCq035DFRUbv3kEJGVrZ4TAlbq/KU8bbv73Sf+87xCE3f/WOO4f9vWve200pU+k78Yrr48Zw3Wzr+3Ky4YBpdtCd1PfkYVq+n4coIoNBz+fE3HGHiyXP+fF8epOcUpYf/nQu9hx6Lyc9g+srnuMete/rea3nMeR/z41k+f8QxNw3csiD/t+IgjqVpgvFk4tm4d+Y+vjQKphsZGRnZ6RsJ1ApxegLVMN0li/c3K1RfRe6YV/iYJp9vVPzC3MpeVd7HJVCz9/Pdv/iYSj/ZGmUZnvMb2PDFL0IIiOf47suMX6eejd3sv8p2UfPrbQEUeq73XDQ37eT1Vlryc2LTwzzHfG/cY777yN9i8jOUvr7wc7PFWzY93He9TDxj80eeX1gWfOc5olXF3xs+GQdfGoXSjYyMjKwChj5s1pk/gaorJLPS95g6T1duqhL1XKfG1+H4u7W7sPGRLRijBKolXjy/u606xm+W4PD8z8/ziRW3ko0RNJ7/fedkj7ktV64F4lcoBGTaetLFMt3tj8JDjnPkXcMqnI7o9D43+zEQPl92J+uhAKp7WXU3F6UHmu+dc4+p/z3CahKBGrg283w5dEF3tauhDHrIS0w8mZXKnxJlgQ85SIcpiP/TIQkinp78NM2XRoXvJRkZGdnpGQnUChEtUHUXpy2mXBMVnVlBhwSqM9bQK2IiBGphhRd6frYCdytpft7EAjX//sXHZPh1OqX3FzauQFXPUcLPf44ycxKaGjPqxo9b4Lm+eJrn2+nLxNrqz+CKmkxlTdwqSg/jHCvPw+9BxmLyM5S+wXSXzzfy6XnSg9WfX5E9ByguzQlQMfFMLS5/wmmQPRc/DN6Fn1/5Cb+nPQGKGY+nIVh95kuLYPqQkZGRnb6RQK0Q8QKVGZ/YwSqX4DJSUnRavwcqxYwIGFOgKoHGK/i09Qivffqb/w73mBjwiyN5b0MAeM8bW6CqiUv59485Jv5n93dnUj+9B9fXNuBPmXRjFiME1DmZGeQsH6/fYtf9ET6+3jUmMMk0kyJLhCvyuaHjPO1MkYzvUNO+p2P56fGApZnvnQuLs4x589OOezh9Q8/B9/RcKuiwLF10xv86VhzP8vkjjhWVBTFJ6qIj0G1T8XRXWcBrP4A1jLsvjYLpRkZGRnb6RgK1QpQSqMz0TGJnOaLwQv1KQDoVtqqoZKWYLleDFeoD+E2vzypHKXitGcZZE5OEsJXHNCZYnVn8fPklNdOfd1mmM/9VpXzeui69tzXTXAoY3bql4+LM4n/DTAt1f1P4SGFgCQZPONQMdCt+zPRyXfJ3vYzSnyH5+F+gibP4+XlO66o21Sru3FenN+bdRWPJKzHj+w2VFjwdZNif/hZ69/5nmjYZAWLE6+pH4n5y1rn+H89T12fChEJNLk9UlB7ed069AxEtxioMxrusurz1exiMJzP1IadXVZDDFPT/Kt+NsGtjgk+ld1Q8S+ZPVFlQ6ec8lz87XarLX+6MsuJLI5026YcbGRkZWVUMfdisM7cClRuOHeV75EsBhIatcO5Wp0q4qXOc1lG1dI/uPuTL96iW0D84laTb6mMau1fR+ppqvKu8n70TlmoNUs9idvE9uMvHxJrH2rCxIVq19DEl/nCiF66LyY9jHMx1Lz2C5OK/wNp/s5959spH8HvnPC1mM+F3W9U2YI0LfPY7ioh//wjeu/hj7+QZ25h4MtdBtVpT/wgfr90JrAWKv6dLFKFIehRKm7xnrd1Lxal1T+M+2ox3IJQe3ndu3XmXnFZf16SwOvt/vQcfqCWujHRRLZv6fp4PAHt9UGxlXLPXL1VLT5n30WYI69x8L5c/Op1zywKaWTY9ZgjObDxFa6o3jX7/kRCs5jHvhxMZGRnZ6Rj6pllnvgUqGdnUjImqtVvwG/PjQhq29LWufZzT7XxMpgRqbhf3hPZ0HdbW+rqlPjVsbV2Fa3kCeuqGAvXXsPYbT0sztnq3/oWEJRkZWS2NBGqFIIFKVh3DIQf/BG+GWsp1N7Xnt+O0aQtU3nX/VmAsLBOHcux09reTMd51/2ZojOif5PAb329kZGRks20kUCsECVSy6pgcH+nZehNnqX/4oTscYDrmHXd8nKZ2kcpsf4pDIH4tdzEzzj9RYwKZjxUODJP58NfOFrtkZGRk9TESqBWCBCpZpYyLIHt8M46R/CCzV/w0zDdWONSSOJlxwa3HLKPh+M2i8cInZSiUb0Fbjy1l5htjTkZGRlYzQ38365BAJZuaUZ6QzbtRGZgvo/wmq4qRQK0QmBlkZGRkZGRkZGQkUCtDHTKjblCeEPMOlYH5gvKbqAokUCsEOYbqQXlCzDtUBuYLym+iKpBArRDkGKoH5Qkx71AZmC8ov4mqQAK1QpBjqB6UJ8S8Q2VgvqD8JqoCCdQKQY6helCeEPMOlYH5gvKbqAokUCsEOYbqQXlCzDuzVAaO9ndgvXMbBgdH8kgdeQWD7k1YH+7DNGJ54vl9tA/D9ZvQHbySB06Zg23odjZguP+9PECcFiRQK8Q4mXE06kOTXYfXCrsAbbegH45gq9uCBfx9oQW9nXKOrfgZ38P+MIFu65z4nT2juzWCQ/nrLIPxGY/XMOwuwZlmH0Z1riuJ2lOuDKAv2IB2Y0H6iia0+wMYHUYUAi5U2tDg1y1Ao11GJBzB4e46tJodSEYH8hgD77n5CPrtJiy0B2D8EsYKB7NGG/qD4/BnLIzDHrvvZeiPvpPHQjjpyMJgCdLDXUjal6HV//LY/Wx5n/cdjPqXRTiVLXTiPhIOv4R+6zK0k10rHkf7Q9hM7rP4X8rWZ0XE5Hnuu8byaZRAu7kC/d2oN4aYEuXfxeox+zGQlM8MKYKUU0BzHQN3AA3tyI72t6DTWILOYC9SpBY9QzrdhqoYZEWxcA6Wk28in1FdML7lURURSysSqMSME18G8L3fgO76Duzzd56JrJ07zBecgYXlBPZyywHzM/07Wlwe7X8GPfbBW3yd4GgvgeXm+zCwBO0rGHRWof1uk8chTqBiOG6nYpAJmZ0eftwfgz873IEuF5xFAlWmoxJtKgwLq5DsGfE7+gaS5cax+9nSPk/HK60jotKah/9yti46GEBn+V14l9/T0+CSS0yex71r/J1adNKcOFFKv4sVZPZjICmbGViAVlbyHPj3sJeswoIlko5Y+e8wZxf3hVv4jKNd6DcXodnfNZyMfK7rUGeQsQoIOuxWC1roYEmgEjNOdBk4GsHm5sgRS6p1LV+UHe39FTZfvJb/ISX8FBc6zbCQYYKnjSI5QjQdjZ7BphtO7uMmLcv4ob8CrVajMC3g6CUMNr+wW0Z5HLJibRoiqpzPQ1/fhpXSIlnUEYvBPJH5X1qgSnLyPP5dk2GM/Egijh8SqBWiXGakLZsLrS488nVBSceaKaQBZ5el+Bmi+9/jOAPHZ43yBYSlWe8WJC+/OIZKjSBOn8kqiXIfxCnoe96GRncn69csZG9F3v1LCFQ/r2DQvjDB9RjGu9BJdmE3QqxnkXFs9GCYGSqBYbvkNBBMRqn81q2n56DVfQgDc3hFHvy6vO776QnULDnvGr9P2fwijovJfE81mP0YSMpkBv9yZgUQr1G20FqHXcOBCZG4kHVekYW3+Bk5TmTiSqEaYJzjMVoTjqXVhSBOn3JlwEW0oJbxAzj+MOkuQ7OzJYcK5BEhHif1RbwsjzEWUpL2QsW1JlvgWMmkC63M8AXFuB8AYeLzW/aUybpBGBOqheNiY8J8MgK1+F2b9OOEmITJfE81mP0YSMbKjMMRDPhgcvyKZQXS6I4ItmKGWlZD5Dwj6Aj4cY84njHK5MnR3iZ0bkhHRwKVqAkTVRJYDpZ+EdkF7Uy20ePac+DlzB1i5DChQEU/ujRuNy8OP+h0pbgsJ1CF/1bCr5mZSKQQ5x1fK1/5/D5iVcQ2JH016ahovK5Mh1zfOG2BGvuuxYSVmBbl38XqMfsxkEyUGUd7MOjgwPDUUUUJVCWkVEFFCxVGzzPSYQDNdLC7niE5pnOpENF5wiuiu2kXHAlUoiaM75fGHZ94AKNBX3wQF41jj/kQnkSgYrleaY85xhPjfwt6QzXesZxAFaD4G/AZ6SHhF/TzYzJ+frOw8Em4RX5PtEqOK1Bt4Y42fi9h8bsm8+wYW6iJeCZ5F6vC7MdAMnFm8EKZFuig4zILbxmBijjP4OiZrng9LivzUDjUGhTquDxxKyIGCVSiJoznl5iw2n0I3fXxl0ES/itffMacEy9WXA5gd/02rJtLDfn8pc+Y7/vz//8H6PTMcY3jCFRJjj+JSoMSYPjHJ6L7Pso3npRAFYTTcII8IyZmsnexGsx+DCQTZwYv+O+kBYn/7+n+8onMWNxn+OAD4C/MzzJT0hmmDjNrY7XeEEQFwPe3LNZwl3EJ+S8TXvamIVDxo/Mm3Ihejs9FthI6fsCyUh/w4a5mIa7G9OceMGyTwMOTKz4na0GNomyeB981akE9TSZ9F6vA7MdAMnFmsELZsZaE8jk1WfC9M0IjyDzDgS8gvQSNqAkO1WfsPOEOj1pQidmnbBk42h9Arzewyz8OD7q9Wa4scJFR0HIVLWLLCNTvYX9wF3qOOMV43U7cZbTKMElrHIo6/2x9IVCPr4VvsnoI65ebBcM6wmI75YQFavBdiwkrMS1IoFaI+MzAXUaeQLI51JUAX2y4rQbjG8jWTDGzEsczJdCOWqi/xDMQHHe6iROp2LN6n9VCnCIkUIl5J74MKP/i6wI3Wznl7G895k+KEXMHuuidkiJmWeeJFb6GqrlI+wGMko6c7OPapCLQJ1DdtGDw8OKyTc/kDlwiTE1nlRaBSrvja+HDuEbBfX4Cm3qHK9yY4S60C1vOY8I8LYFa9l2LeL+IqRH9LlaY2Y+BJD4z0h1auOPEwvZoO7idIN+fmg+yZ+e6W+YFiXyGdASl18GbEcYuICRQiZoQWwZ8y9KllifKcLwq7j6nzsWtJ+8bwicPdm1wHVQlCEPhYFgCVYbLOt+wictypEDlu//JbaPRcKtVo6HARrSsFq8XGw8+Mwpr7gETg6H1uH3krYOqfKeKP1p02hflecl3jddvS9A15xcQJwbm0awz+zGQ1CEz6gblCTHvVL4McJGZs5NUnUEBdao7SY2LEObhnaSqgGhtpZ2kTg8SqBWCxFD1oDwh5p1ZKAO89Ta4mH1N4cv+XT79vfjHhX9YePbirwh8yaxm7Bq+xDQggVohSAxVD8oTYt6ZjTIgu26bEYv714HoMbrlOdH85sMZLgc3ITgd5Fjq5gr0zSXGiBOHBGqFIDFUPShPiHlnlsoAH2/fuV3zJYFewaB7M3IuQXlOPL/5xi43oVuVIRoH29DtbMBwnlrjKwoJ1ApBYqh6UJ4Q8w6VgfmC8puoCiRQKwRmBhkZGRkZGRkZGQlUgiAIgiAIgjhWSKASBEEQBEEQlYIEKkEQBEEQBFEpSKASBEEQBEEQlYIEqo8q7q5yOIJBgvv1v2NvNzgWr2HYXTL20CamS2R6H2seEwRBEMTsMgcCVYiDUntB8z2EF6DZ3/WvlYdrzyXddE9i3O8Z91E++BySbVPUHsHB9qewPfG6grhn9AU5M8/ZD3ssSKCeLKH0fgXbyedyu8LjzuPTwIwPQRAEQYxPzQXqERwOe9DASr9QoH4Ho/5lJjZxy789JhZWmEj4O+z2l2FhoWMsXi0Fb8PYdYUvltxmz7lgt7piS+zKzWNa+FqGb2bFC+GCW0yudMz9tGc7j7PxIQiCIIjxqLdAPdyBbqsFrcZCVAvq0f4QNpMEHvXvQ6/TgVv3+7DO/t80dx0Jtq5+D3tJBzpaoB54xO0kkECtFXybwnOw0K6JQPXGhyAIgiDGo8YC9TUMe7cgefkF9JtxAlWMAXwE6/0+3A8I1KNRH5pnzvi7x3UXvxSnvLtW2sIqdG/9Z/m/amlVggSPuaIX9zR+xgT2Of5bo7MJg/tKvLw2rjPvl4aPHw/EmQvxfhsa+nd81jY86rZggR3b3duB9XaT32OhdQd2vNvWHTGt3jHiiOH61jmmwmV0X2vBbsYPz21Cuz+A0aEK8AGMBgn020ssXb6CAzMt2gk77wfr+kw4das23huvUdvvnXxcM+ktxZy4TpgQdqZA/TuM2AcPD/9CC3o7OVsz4nv7CIecsOt2/5bG23sdS9etXnZ4ivzVxnw/c97ZYHyQ72F/uAFt/EjE39jz0m0mzTz+AvYG77Nwn4PWL1dlvqX38b/X7N47d0RceI/G1zDoPSwu5wRBEETlqalAxdbMNqwk38DR0W6kQBUVrxApaRc/FwlmKyifQCUrY6uydZEVudWCiuFaZaImFZTpMVugYnfp8kITOoM9doyJqt1PoN1E4YPiBVvXWOXMK3TzXgg7d9iDZmh8KW8Bdip681hjBbrrn8M+Oy7CkDMWl+E9x5fmmG6duzDkAlSEsbGwzAQVlx8sfutcaAjhbwpCFJf35UeCijMTMbfuQn9zlwurTBiOWP51VqCdyN/3P4MeCigMzz9OOK6+9ObniOv8LagNWO5+IsSyet/May3MsatF18mxsK112OX5oD6kzsEylhVxkkPkO+uND+bXTWjxDwp2Fvto2OmxD4OMwGd5vHwbBi//xvJtCRrdHTjgaW0KXXa5PKbihKJ1ScdFvhvBdCIIgiBmiVoK1KO9Tejc2OLCwysgiiiaJHW4C4lsdRNCx9cK5ROoSnjZolK0DpmVPYqLC87zlXhRAhUR4sRuzcVjKK5zuoi9oiryWAYpkKxz5DEz7gfb0Fs3xcyiE79s2mTSBZGCzxJCTji5cLGEknPvk4wrkvM8v0A189h3zCXuOpGe7n084beIfWc98cFjSzfs+zr5581jpDCfRbgW3XefWlAJgiBqQf0EqtVSh/97xEERXCC+A93ha3nAx/d21yUzu4tYCoQxBKr43z4nJFTEuUtpWLFiXyqIqy9NYo9lUHEywiXFRdotjOfch3VLKLnxY8SIl0LhotJJfjxYJu91gnHl5DzPikek0MwSc538PyNE/e9kiv/3TN544iPOcfNAmkwLbx4jhfmc3n+h1YVHwWEKBEEQxCxSM4GKXY+3oGcKyyjhMQk4jq6vhWramukTBDGVfUgwBISK7MoVFTmes5zTXSvJEUyFx3zgZLSGahHFPOhAZ2ubXyvCZbZs5QgirwApK1BFi6D1u8uJxVWS8zw7nL48DuS7Rcx14ZbSoEjkjCtQ5XXBlllB8NkRApV/JKoxqCh6zZU1CIIgiJmmXgJVt2aFLVe4xJBZ61SixvxpQSAFwrQFKjtfLKXFju++yHap+sgRTGOJNhU2PO8Hds3ybRgefpvG/+XA6vIOihJH5HjPKxQuMiyNXtqK7nKCceXkPM9+H315HMp3k5jrwvcR6ez5YOCMK1DVOUbrvofguxAlUCXmusQLq5Ds+Sa6EQRBELNETSdJGUQLj0hYxdlZ8U1AkgJAC1L3fySysvdVzjkCQ4uDRgMa1jUBfGkSeyyAiMNluJ/cgRUZD3HsHLzTWjaW32KE7svjnQoar3iJEC7iOnZOqwdbZova4RDWk9EEXfyCUnFFcp53cgJVhdEVg/KdDAr68QWqjvdCC7pbZhf8axiuf2rk1TgClYVr+yFsmmKUXxMS2gRBEMQsQQK1LLwSxJnlfRho8XMEh6ME2o0L0Op/KStiVbGjQPgWDl/8FYYoVNX1HTGJSy9BZLXwqlnS56DV+0yetw291iV+TjreUWE+KyRiDHg3NQoHQzxLQWClkzovrzVSocWI0YKlj5kiHVGtvmk6iJn3S+n/5jndHS1u1Exua2KYCrsKp27NFmmqTYXtROPK8KW36nLnYXgNLwZfsHyXx6xWR7kxRG5LpLrOzH/fdeqYWh2CBXt/CzqNJf2/l6h31hcf9R4becBNrRqg3luPQFX34xtnsDTGVtJN3AaWpSPeY+GX8OjRL2FRj/uWK0EsUgsqQRBEHSCBWhbZxe9W0t6Z/Gp9SGs9ygNrfUtsWTrAViS8Ptm21wFV53GhusXXQQ1NCOEtUTFxVOJMhZuJmnvJbbAms6CQerlln+cTXhaixc7XImgfUziTzDAtkqEUp6r1z3h+8z7sbKGYMY/1YXcXW+CMYyqc1jqoaWuqaLFzzp9mXD3pLUSkFFTsNz65bk+u16vPw4+Qr6TwNI8FWmdjr8ukSxeSYWipNEXMO+vER08W9OQzb03N5rGddux+/KMPr2Pvf/cZjA6+YnFdgnY/YR+H/xDbCO99la6oQWNQCYIgakP9BepcgC1RN8W6r/IIQRAEQRDErEICtQbwbtpmxOQogiAIgiCIGYAE6qyixjXy7tG8nYAIgiAIgiBmCxKos4qeCNTUW3oSBEEQBEHUARKoBEEQBEEQRKUggUoQBEEQBEFUChKoBEEQBEEQRKUggUoQBEEQBEFUCID/DUBhwikb+b/pAAAAAElFTkSuQmCC" /></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The risk of coronary artery disease is slightly increased in users of combined oestrogen-progestogen HRT over the age of 60 (see section 4.4). There is no evidence to suggest that the risk of myocardial infarction with tibolone is different to the risk with other HRT.</p><p><img width="754" height="166" alt="" src="data:image/png;base64,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" /></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gall bladder disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and subcutaneous disorders: chloasma, erythema multiforme, erythema nodosum, vascular purpura</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Probable dementia over the age of 65 (see section 4.4)</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The acute toxicity of tibolone in animals is very low. Therefore, toxic symptoms are not expected to occur, even when several tablets are taken simultaneously. In cases of acute overdose, nausea, vomiting and vaginal bleeding in females may occur. No specific antidote is known. Symptomatic treatment can be given if necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: urogenital system (including sex hormones), ATC code: G03CX01 <u>Mechanism of action and pharmacodynamic effects</u></p><p>Following oral administration, tibolone is rapidly metabolised into three compounds, which all contribute to the</p><p>pharmacodynamic profile of Livial. Two of the metabolites (3a-OH-tibolone and 3b-OH-tibolone) have oestrogenic-like activities, whereas the third metabolite (D4-isomer of tibolone) has progestogenic and androgenic- like activities.</p><p>Livial substitutes for the loss of oestrogen production in postmenopausal women and alleviates menopausal symptoms. Livial prevents bone loss following menopause or ovariectomy.</p><p><u>Clinical efficacy and safety</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Relief of oestrogen-deficiency symptoms</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Relief of menopausal symptoms generally occurs during the first few weeks of treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects on the endometrium and bleeding patterns</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There have been reports of endometrial hyperplasia and endometrial cancer in patients treated with Livial (see section 4.4 and 4.8).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amenorrhea has been reported in 88% of women using Livial 2.5 mg after 12 months of treatment.</p><p>Breakthrough bleeding and/or spotting has been reported in 32.6% of women during the first 3 months of treatment, and in 11.6% of women after 11-12 months of use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prevention of osteoporosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oestrogen deficiency at menopause is associated with an increasing bone turnover and decline in bone mass. Protection appears to be effective for as long as treatment is continued. After discontinuation of HRT, bone mass is lost at a rate similar to that in untreated women.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the LIFT study, Livial reduced the number of women (mean age 68 years) with new vertebral fractures compared to placebo during the 3 years of treatment (ITT: Livial to placebo odds ratio 0.57; 95% CI [0.42, 0.78]).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After 2 years of treatment with Livial (2.5 mg), the increase in lumbar spine bone mineral density (BMD) was 2.6 &plusmn; 3.8%. The percentage of women who maintained or gained BMD in lumbar zone during treatment was 76%. A second study confirmed these results.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Livial (2.5 mg) also had an effect on hip BMD. In one study, the increase after 2 years was 0.7 &plusmn; 3.9% at the femoral neck and 1.7 &plusmn; 3.0% at the total hip. The percentage of women who maintained or gained BMD in the hip region during treatment was 72.5%. A second study showed that the increase after 2 years was 1.3 &plusmn; 5.1% at the femoral neck and 2.9 &plusmn; 3.4% at the total hip. The percentage of women who maintained or gained BMD in the hip region during treatment was 84.7%.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects on the breast</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In clinical studies mammographic density is not increased in women treated with Livial compared to placebo.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption and biotransformation</u></p><p>Following oral administration, tibolone is rapidly and extensively absorbed. The consumption of foods has no significant effects on the extent of absorption.</p><p>Due to rapid metabolism, the plasma levels of tibolone are very low. The plasma levels of the D4-isomer of tibolone are also very low. Therefore some of the pharmacokinetic parameters could not be determined. Peak plasma levels of the 3a-OH and the 3b-OH metabolites are higher but accumulation does not occur.</p><p><img width="820" height="346" alt="" src="data:image/png;base64,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" /></p><p><!--[if gte vml 1]><v:group
 id="Group_x0020_22" o:spid="_x0000_s1046" style='position:absolute;left:0;
 text-align:left;margin-left:106.45pt;margin-top:19.05pt;width:382.7pt;
 height:.1pt;z-index:1216;mso-position-horizontal-relative:page' coordorigin="2129,381"
 coordsize="7654,2" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAZUN9o3wDAACKCAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWysVtuO0zAQfUfiHyw/grq5NL2K7Grp
ZYW0wIqWD3ATt4lw7GC7NxD/zniSbNNdChKQh9SOx2fOHM94+ubmUAiy49rkSsY0uPIp4TJRaS43
Mf28nHeGlBjLZMqEkjymR27ozfXLF2/YeKNZmeUJAQRpxiymmbXl2PNMkvGCmStVcglra6ULZmGq
N16q2R6QC+GFvt/3CpZLen2CmjLLyFbnfwElVPKFpxMmd8wApEjG7S81R5H8OzIby92dLhflg3bM
kw+7B03yNKagnGQFSES9eqE2g6n3ZNfmBHBY68LZq/WaHOAEur1gFPQoOcY08vuDYNCr8PjBkgQM
omHfD0fgLAGLIBz4tbvs4x8Akmz2OwigWFGBQYseDh2/C1GHQRP2nVbbkoTh0/DdZkS5hyMylRig
2l0jwQVtyGr/XqUgJ9tahUnyv5UKg3CEOneHQSNiI9Gg34sqiTGeC+KYslLmeTKADHU2zDXnrgRI
2H1UprE35bkm1XcU5GQC6fUnKZ5H0mTLpTggcbfG3nGFucd298Zi1m5SGOGJpTX/JaTauhBQ3q87
xCfOFb6qYDaPZpAHldkrjyx9sifougZtsECVFtZoMAx/idVtzBxW2MJyudkwZFlDOjnImjWMCHM3
l48ZUyrjamoJ3KBYsFIAAYxchBdswfdT22pP7ULzxBKB5W7xrWOqKVnFdFVJUjLrmDkXbkj2MUUp
3IdC7fhS4ZJ1zEDblrPTqpBtK9h+zqpaBlrOAd4uj04d19bJSjXPhcBTEBKpdPt91MYokadu0bEx
erOaCE12zEWGjwsGwM7MoMJlimAZZ+msHluWi2oM9gK1hfSrJXCJiDf695E/mg1nw6gThf1ZJ/Kn
087tfBJ1+nO446bd6WQyDX44akE0zvI05dKxa7pLED27uos80cqotb1KVOHB/ZknvOkw0F8C/9Rf
zqI4C3aOz/NgvXMaqAXE0vxidE6eug3YwwLvAnt4q9Kjk3QFv1C6WlVZAi0WBpnS3yjZQ+OMqfm6
ZZpTIt5JE9NREEWQDRYnUW8QwkS3V1btFSYTgIqppZDubjixMIMt21Lnmww8BXjIUt3C7bnOXXED
24qTYyeMXdij4HiYyJzL9IFp9gk4CywhLjufF7UwYAHbT8FtDV+Un6ASKtwqepQDDeum4T3pwvUa
/mtwrb49v/4JAAD//wMAUEsDBBQABgAIAAAAIQDhUTcfzwYAAOYbAAAaAAAAY2xpcGJvYXJkL3Ro
ZW1lL3RoZW1lMS54bWzsWc1v3EQUvyPxP4x8b7PfzUbdVNnNbgNt2ijZFvU4a8/a04w91sxs0r2h
9oiEhCiIA5W4cUBApVbiUv6aQBEUqf8Cb2ZsryfrkLSNoILmkLWff/O+35uvy1fuxQwdECEpT3pe
/WLNQyTxeUCTsOfdGo8urHpIKpwEmPGE9Lw5kd6V9fffu4zXfEbTCcciGEckJggYJXIN97xIqXRt
ZUX6QMbyIk9JAt+mXMRYwasIVwKBD0FAzFYatVpnJcY08daBo9KMhgz+JUpqgs/EnmZDUIJjkH5z
OqU+Mdhgv64Rci4HTKADzHoe8Az44ZjcUx5iWCr40PNq5s9bWb+8gteyQUydMLY0bmT+snHZgGC/
YWSKcFIIrY9a3UubBX8DYGoZNxwOB8N6wc8AsO+DpVaXMs/WaLXez3mWQPZxmfeg1q61XHyJf3NJ
526/3293M10sUwOyj60l/Gqt09poOHgDsvj2Er7V3xgMOg7egCy+s4QfXep2Wi7egCJGk/0ltA7o
aJRxLyBTzrYq4asAX61l8AUKsqHILi1iyhN1Uq7F+C4XIwBoIMOKJkjNUzLFPuTkAMcTQbEWgNcI
Ln2xJF8ukbQsJH1BU9XzPkxx4pUgL599//LZE3R0/+nR/Z+OHjw4uv+jZeSM2sJJWB714tvP/nz0
MfrjyTcvHn5RjZdl/K8/fPLLz59XA6F8FuY9//Lxb08fP//q09+/e1gB3xB4UoaPaUwkukEO0S6P
wTDjFVdzMhGvNmIcYVoesZGEEidYS6ngP1SRg74xxyyLjqNHn7gevC2gfVQBr87uOgrvRWKmaIXk
a1HsALc5Z30uKr1wTcsquXk8S8Jq4WJWxu1ifFAle4ATJ77DWQp9M09Lx/BBRBw1dxhOFA5JQhTS
3/g+IRXW3aHU8es29QWXfKrQHYr6mFa6ZEwnTjYtBm3RGOIyr7IZ4u34Zvs26nNWZfUmOXCRUBWY
VSg/Jsxx41U8UziuYjnGMSs7/DpWUZWSe3Phl3FDqSDSIWEcDQMiZdWYmwLsLQX9GoaOVRn2bTaP
XaRQdL+K53XMeRm5yfcHEY7TKuweTaIy9gO5DymK0Q5XVfBt7laIfoc44OTEcN+mxAn36d3gFg0d
lRYJor/MhI4ltGqnA8c0+bt2zCj0Y5sD59eOoQE+//pRRWa9rY14A+akqkrYOtZ+T8Idb7oDLgL6
9vfcTTxLdgik+fLE867lvmu53n++5Z5Uz2dttIveCm1XrxvsotgskeMTV8hTytiemjNyXZpFsoR5
IhgBUY8zO0FS7JjSCB6zvu7gQoHNGCS4+oiqaC/CKSyw655mEsqMdShRyiVs7Ay5krfGwyJd2W1h
W28YbD+QWG3zwJKbmpzvCwo2ZrYJzeYzF9TUDM4qrHkpYwpmv46wulbqzNLqRjXT6hxphckQw2XT
gFh4ExYgCJYt4OUO7MW1aNiYYEYC7Xc79+ZhMVE4zxDJCAcki5G2ezlGdROkPFfMSQDkTkWM9Cbv
FK+VpHU12zeQdpYglcW1ThCXR+9NopRn8CJKum6PlSNLysXJEnTY87rtRttDPk573hT2tPAYpxB1
qdd8mIVwGuQrYdP+1GI2Vb6IZjc3zC2COhxTWL8vGez0gVRItYllZFPDfMpSgCVaktW/0Qa3npcB
NtNfQ4vmKiTDv6YF+NENLZlOia/KwS5RtO/sa9ZK+UwRsRcFh2jCZmIXQ/h1qoI9AZVwNGE6gn6B
czTtbfPJbc5Z0ZVPrwzO0jFLI5y1W12ieSVbuKnjQgfzVlIPbKvU3Rj36qaYkj8nU8pp/D8zRc8n
cFLQDHQEfDiUFRjpeu15XKiIQxdKI+qPBCwcTO+AbIGzWPgMSQUnyOZXkAP9a2vO8jBlDRs+tUtD
JCjMRyoShOxAWzLZdwqzejZ3WZYsY2QyqqSuTK3aE3JA2Fj3wI6e2z0UQaqbbpK1AYM7nn/ue1ZB
k1Avcsr15vSQYu61NfBPr3xsMYNRbh82C5rc/4WKFbOqHW+G53Nv2RD9YbHMauVVAcJKU0E3K/vX
VOEVp1rbsZYsbrRz5SCKyxYDsVgQpXDeg/Q/mP+o8Jm9bdAT6pjvQm9FcNGgmUHaQFZfsAsPpBuk
JU5g4WSJNpk0K+vabOmkvZZP1ue80i3kHnO21uws8X5FZxeLM1ecU4vn6ezMw46vLe1EV0Nkj5co
kKb5RsYEpurWaRunaBLWex7c/ECg78ET3B15QGtoWkPT4AkuhGCxZG9xel72kFPgu6UUmGZOaeaY
Vk5p5ZR2ToHFWXZfklM60Kn0FQdcsekfD+W3GbCCy24/8qbqXM2t/wUAAP//AwBQSwMEFAAGAAgA
AAAhAJxmRkG7AAAAJAEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1s
LnJlbHOEj80KwjAQhO+C7xD2btJ6EJEmvYjQq9QHCMk2LTY/JFHs2xvoRUHwsjCz7DezTfuyM3li
TJN3HGpaAUGnvJ6c4XDrL7sjkJSl03L2DjksmKAV201zxVnmcpTGKSRSKC5xGHMOJ8aSGtHKRH1A
VzaDj1bmIqNhQaq7NMj2VXVg8ZMB4otJOs0hdroG0i+hJP9n+2GYFJ69elh0+UcEy6UXFqCMBjMH
SldnnTUtXYGJhn39Jt4AAAD//wMAUEsBAi0AFAAGAAgAAAAhALvlSJQFAQAAHgIAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEArTA/8cEAAAAyAQAA
CwAAAAAAAAAAAAAAAAA2AQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAZUN9o3wDAACKCAAA
HwAAAAAAAAAAAAAAAAAgAgAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBLAQItABQA
BgAIAAAAIQDhUTcfzwYAAOYbAAAaAAAAAAAAAAAAAAAAANkFAABjbGlwYm9hcmQvdGhlbWUvdGhl
bWUxLnhtbFBLAQItABQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAAAAAAAAAAAAAAOAMAABjbGlw
Ym9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHNQSwUGAAAAAAUABQBnAQAA4w0A
AAAA
">
 <v:shape id="Freeform_x0020_23" o:spid="_x0000_s1047" style='position:absolute;
  left:2129;top:381;width:7654;height:2;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="7654,2" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l7653,e" filled="f" strokeweight=".58pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;7653,0"
   o:connectangles="0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--></p><p><u>Elimination</u></p><p>Excretion of tibolone is mainly in the form of conjugated (mostly sulfated) metabolites. Part of the administered compound is excreted in the urine, but most is eliminated via the faeces.</p><p><u>Other special populations</u></p><p>The pharmacokinetic parameters for tibolone and its metabolites were found to be independent of renal function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal studies, tibolone had anti-fertility and embryotoxic activities by virtue of its hormonal properties. Tibolone was not teratogenic in mice and rats. It displayed teratogenic potential in the rabbit at near-abortive dosages (see section 4.6). Tibolone is not genotoxic under <em>in vivo </em>conditions. Although a carcinogenic effect was seen in certain strains of rat (hepatic tumours) and mouse (bladder tumours), the clinical relevance of this is uncertain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Livial 2.5 mg tablets contain potato starch, magnesium stearate, ascorbyl palmitate and lactose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C. Do not refrigerate. Store in the original package. Keep the blister in the outer carton, in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Livial 2.5 mg tablets are packed in push-through packs of transparent polyvinyl chloride film and coloured aluminum foil containing a heat seal coating on the side in contact with the tablets. The following pack sizes are available: cardboard boxes containing 1 or 3 push-through packs with 28 white tablets each containing 2.5 mg of tibolone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                N.V. Organon, Kloosterstraat 6, 5349 AB Oss, The Neterlands.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                22 March 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>